Current Insights on Biomarkers in Lupus Nephritis: A Systematic Review of the Literature

Leonardo Palazzo 1,2, Julius Lindblom 1,2*, Chandra Mohan 3 and Ioannis Parodis 1,2,4,*

1 Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, 171 77 Stockholm, Sweden
2 Medical Unit of Gastroenterology, Dermatology and Rheumatology, Karolinska University Hospital, 171 76 Stockholm, Sweden
3 Department Biomedical Engineering, University of Houston, Houston, TX 77204, USA
4 Department of Rheumatology, Faculty of Medicine and Health, Örebro University, 701 82 Örebro, Sweden
* Correspondence: ioannis.parodis@ki.se; Tel.: +46-722321322

Abstract: Lupus nephritis (LN) is a major cause of morbidity and mortality among patients with systemic lupus erythematosus (SLE). However, promising emerging biomarkers pave the way toward an improved management of patients with LN. We have reviewed the literature over the past decade, and we herein summarise the most relevant biomarkers for diagnosis, monitoring, and prognosis in LN. An initial systematic search of Medline was conducted to identify pertinent articles. A total of 104 studies were selected to be included in this review. Several diagnostic biomarkers, including MCP-1, TWEAK, NGAL, and uric acid, exhibited good ability to differentiate LN patients from non-renal SLE patients. Several cytokines and chemokines, including IL-10, IL-17, MCP-1, and IP-10, hold promise for assessing LN disease activity, as do cell adhesion molecules (CAMs). Angiogenesis-related and haemostasis-related proteins have also displayed potential for monitoring disease activity. Biomarkers of responses to therapy include Axl, CD163, and BAFF, whereas VCA-1, ALCAM, and ANCs have been reported as prognostic markers, along with traditional markers. In addition, novel renal tissue biomarkers may prove to be a useful complement to histological evaluations. The overall heterogeneity of the inclusion criteria and outcome measures across different studies, along with a lack of validation in multi-centre cohorts, call for future collaborative efforts. Nevertheless, we foresee that several biomarkers hold promise toward optimisation of the management of LN, with the use of integrated omics and panels of less invasive biomarkers paving the way towards personalised medicine.

Keywords: systemic lupus erythematosus; lupus nephritis; biomarkers; diagnosis; monitoring; prognosis

1. Introduction

Kidney involvement in patients with systemic lupus erythematosus (SLE), termed lupus nephritis (LN), is a common and severe manifestation of the disease. The prevalence of LN varies depending on age, sex, and ethnicity, among other factors, and it is estimated to be 35–60% [1,2]. The clinical presentation is highly heterogeneous, varying from silent disease to rapidly progressive nephropathy [3,4]. Despite advancements in the understanding of the pathophysiology of LN, as well as in the development of treatment strategies, only 50–70% of patients achieve remission, and LN is still a major cause of mortality and morbidity in patients with SLE [5].

A kidney biopsy is still the gold standard for the evaluation of LN for the confirmation of LN diagnosis and determination of the type and degree of kidney tissue injury and damage [6,7]. However, a kidney biopsy is an invasive procedure, and its utility in guiding therapeutic decisions is limited by the heterogeneity of the etiopathogenesis of renal disease in patients with SLE [5]. Fluid-based biomarkers, that are validated indicators of physiologic or pathologic processes or responsiveness to therapy [8], constitute promising complemental or alternative, less invasive modes for assessing renal SLE.
Traditional laboratory biomarkers include immune serology tests, such as anti-double-stranded (ds) DNA and complement levels, and kidney disease-related parameters, such as proteinuria estimated through 24-h urinary protein excretion or the urine protein-to-creatinine ratio (uPCR), urinary sediment, and glomerular filtration rate (GFR). These are well-established tools for the clinical evaluation of LN. However, they have shown the unsatisfactory ability to detect LN flare development early, as well as limited sensitivity and specificity to discriminate between active ongoing disease and chronic organ damage, which is crucial for treatment planning [9,10].

Recent technological advancements, including assays for broad proteomic and metabolomic analyses, have contributed to a growing body of evidence on new biomarkers, some of which have shown equal or even superior performances than traditional markers [11–13]. This review aims to summarise the literature of the last decade on the topic of biomarkers of potential utility for the diagnosis, monitoring, and prognosis of adult patients with LN.

2. Materials and Methods

An initial systematic literature search was performed to identify the relevant articles addressing the potential role of biomarkers in the evaluation of diagnosis, disease activity, organ damage, responsiveness to therapy, and prognosis over the long term in adult patients with LN (≥18 years of age). Details regarding the search are provided in the online Supplementary Materials (Figure S1 and Table S1), and the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 2020 flow diagram presented in Figure S1 synthetises the key points of the selection process [14]. The search terms are detailed in Table S1. The search strategy was applied to the Medline database, and studies in English published between 1 January 2012 and 13 June 2022 were assessed for eligibility. The study designs deemed eligible comprised meta-analyses and randomised controlled trials (RCTs), including post hoc analyses of RCTs, quasi-experimental studies, cohort studies, and cross-sectional studies. Animal studies, preclinical studies, studies of qualitative design, case series, case reports, studies on paediatric LN, and studies focused on comorbidities were beyond the scope of this review. The assessment for eligibility was performed by two investigators (L.P. and J.L.). Ambiguities were discussed with a third investigator (I.P.) to arrive at a consensus.

Ninety-three reports met the inclusion criteria, and fourteen additional articles were selected based on an expert opinion (C.M. and I.P.), yielding a total of one hundred and seven studies included in this systematic review. To evaluate the risk of bias (RoB) within the included studies, the Joanna Briggs Institute (JBI) Critical Appraisal Checklist for Analytical Cross-Sectional Studies, the JBI Critical Appraisal Checklist for Systematic Reviews and Research Syntheses, and the JBI Critical Appraisal Checklist for Cohort Studies [15] were used (Supplementary Tables S2–S4). The ethnic characteristics of study populations for each one of the studies included in the review are provided in Supplementary Table S5.

3. Results

3.1. Diagnostic Biomarkers

Autoantibodies and immune complexes are hallmarks of SLE, hypothesised to be directly involved in the pathogenesis underlying organ injury in SLE, including LN [16]. Anti-dsDNA and anti-C1q constitute well-known autoantibodies that are widely used in clinical practice and recommended by guidelines as surveillance tools [6]. Additionally, new autoantibodies are emerging, among which anti-α-enolase (anti-ENO-1) antibodies deserve mention. Anti-ENO-1 form as a consequence of α-enolase externalisation during NETosis [17]. In a study by Huang et al., anti-ENO-1 displayed a good ability to predict the incidence of LN in SLE patients (area under the curve (AUC)= 0.81; \( p = 0.001 \)) [18]. Interestingly, studies conducted by Bruschi et al. revealed a higher prevalence of the anti-ENO-1 IgG2 isotype in LN patients compared with subjects with other glomerulonephritides, as
well as in patients with LN, compared with patients with non-renal SLE (AUC = 0.82; p = 0.02) [19–21].

Hyperuricemia, a marker of renal dysfunction, has recently been hypothesised to be involved in LN pathogenesis [22]. Consistent results across different studies lend support to a diagnostic role of uric acid (UA) for distinguishing LN from SLE with no renal involvement (AUC = 0.80–0.86; p < 0.001 for all; sensitivity (sens.): 75–83%; specificity (spec.): 70–79%; positive predictive value (PPV): 70–87%; negative predictive value (NPV): 62–80%; cut-off values: 4.47–5.54 mg/dL) [22–24].

Tumour necrosis factor (TNF) weak inducer of apoptosis (TWEAK) is a cytokine member of the TNF superfamily involved in multiple cellular processes [25]. It is postulated that the main source of TWEAK in LN are innate immune cells, mainly monocytes and natural killer cells, which infiltrate the kidneys during inflammation. TWEAK exerts its action by interacting with its sole receptor, Fn14, and activates multiple intracellular pathways, which vary depending on the cell microenvironment [26,27]. TWEAK has been linked to LN pathogenesis and represents a possible target of renoprotective agents [28,29]. Pathological effects mediated by TWEAK/Fn14 signalling include the enhancement of apoptosis of parenchymal renal cells and induction of proinflammatory cytokines and chemokines, which, in turn, might serve as emerging biomarkers of kidney injury in LN [27,30]. Both serum and urinary TWEAK hold promise as useful diagnostic markers of LN, with the latter displaying outstanding overall metrics in most studies (see Table 1 for the detailed metrics) [26,27,30], although two studies reported the superiority of serum TWEAK over urinary TWEAK in the ability to differentiate between LN and non-renal SLE [31,32].

Neutrophil gelatinase-associated lipocalin (NGAL) is a small secreted glycoprotein whose expression is upregulated in several pathologic conditions, including inflammatory and renal diseases [33]. NGAL is functionally involved in the induction of apoptosis and iron sequestration, thus playing a critical role in innate immunity in the context of bacterial infections [34]. With regard to LN, NGAL is highly expressed by activated leukocytes and tubular epithelial cells in response to inflammation and kidney injury [35]. NGAL may act as a nephroprotective agent by modulating apoptosis in resident macrophages and tubular cells in the context of a renal insult, although a definitive mechanistic explanation for its function in LN has yet to be provided [34]. Urinary NGAL has proven to be a versatile biomarker in LN across multiple studies [35–41]. Of relevance to the diagnosis of LN, the urine levels of NGAL were found to be higher in patients with LN than in patients with non-renal SLE in two independent cohorts, exhibiting an overall good diagnostic ability (AUC = 0.70–0.99; sens.: 67–98%; spec.: 63–100%) [41,42].

A growing number of studies have investigated the role of microRNAs (miRNAs) as putative epigenetic biomarkers in LN. These short single-stranded RNA molecules have been implicated in multiple regulatory events of gene expression [43], and differential levels of different miRNAs, including miRNA-21, miRNA-146a, miRNA-150, miRNA-155, miRNA-181a, miRNA-223, and miRNA-423, have been linked to kidney involvement in patients with SLE [44–47]. In particular miRNA-21 displayed a satisfactory ability to distinguish between patients with active LN compared with a group of patients with either inactive LN or non-renal SLE (AUC = 0.89; p < 0.001) [45], as well as patients with LN from healthy controls (AUC = 0.91; sens.: 86%; spec.: 63%; PPV: 76%; NPV: 93%; p < 0.001) [46].

Recently, monocyte-derived urinary microparticles (MPs) have been shown to be promising diagnostic biomarkers for LN, serving as a remote biopsy to assess the retention of inflammatory cells within renal parenchyma [48]. Burbano et al. found a significant increase of MP-HELDR+, MP-high mobility group box 1 (HMGB1)+, and MP-C-X3-C chemokine receptor 1 (CX3CR1)+ in patients with LN compared to patients with non-renal SLE (see Table 1 for the metrics). In addition, MP-HMGB1+ exhibited an adequate performance in differentiating patients with active LN from patients with inactive LN (AUC = 0.83; sens.: 55%; spec.: 93%; p < 0.001) [48]. Interestingly, the aforementioned molecules are mainly expressed by non-classic monocytes, lending support to the hypothe-
sis that this specific cell subset constitutes one of the main drivers of kidney inflammation and injury in LN [48,49].

Table 1. Performances of selected diagnostic biomarkers for LN.

| Biomarker                  | Sample            | Comparator                  | Metrics                              | References                  |
|----------------------------|-------------------|----------------------------|--------------------------------------|-----------------------------|
| **Autoantibodies**         |                   |                            |                                      |                             |
| Anti-C1q (+)               | Serum/Plasma      | Non-renal SLE              | AUC = 0.76; sens.: 74%; spec.: 55%  | Gomez-Puerta et al., 2018 [41] |
|                            |                   | Non-renal SLE              | OR = 4.4                             | Sjöwall et al., 2018 [50]   |
|                            |                   | Non-renal SLE              | sens.: 63%; spec.: 71%              | Birmingham et al., 2016 [51]|
|                            |                   | Active non-renal SLE       | AUC = 0.64; sens.: 47%; spec.: 83%  | Pang et al., 2016 [52]      |
|                            |                   | Non-renal SLE              | AUC = 0.65                            | Bruschi et al., 2021 [20] * |
|                            |                   | Healthy controls           | AUC = 0.94                            |                             |
|                            |                   | Non-renal SLE              | OR = 2.1                             | Hardt et al., 2018 [53]     |
|                            |                   | Non-renal SLE              | AUC = 0.72; sens.: 72%; spec.: 73%; HRadj = 2.7 | Liu et al., 2021 [54] |
|                            |                   | Non-renal SLE              | AUC = 0.89; sens.: 100%; spec.: 71%; PPV: 43%; NPV: 100%; HR = 1.1 | Kwon et al., 2020 [55] |
|                            |                   | Active non-renal SLE       | OR = 2.9                             | Sjöwall et al., 2018 [50]   |
|                            |                   | Non-renal SLE              | OR = 3.3                             | Barnado et al., 2019 [57]   |
|                            |                   | Anti-dsDNA-negative SLE    | OR = 4.6                             |                             |
| Anti-dsDNA (+)             | Serum/Plasma      | Non-renal SLE              | AUC = 0.81; sens.: 82%; spec.: 91%  | Huang et al., 2019 [18]     |
|                            |                   | Non-renal SLE              | AUC = 0.82                            | Bruschi et al., 2021 [20] * |
|                            |                   | Healthy controls           | AUC = 0.94                            |                             |
|                            |                   | Non-renal SLE              | AUC = 0.94                            |                             |
|                            |                   | PHACTR4 icx (+)             | AUC = 0.99                            | Tang et al., 2022 [58]      |
| Anti-ENO-1 (+)             | Serum/Plasma      | Non-renal SLE              | AUC = 0.81; sens.: 82%               | Huang et al., 2019 [18]     |
|                            |                   | Non-renal SLE              | AUC = 0.82                            | Bruschi et al., 2021 [20] * |
|                            |                   | Healthy controls           | AUC = 0.94                            |                             |
|                            |                   | P3H1 icx (+)                | AUC = 0.99                            |                             |
|                            |                   | RGS12 icx (+)               | AUC = 0.90                            |                             |
| **Complements**            |                   |                            |                                      |                             |
| C3 (low)                   | Serum/Plasma      | Non-renal SLE              | HR = 6.4                             | Liu et al., 2021 [54]       |
|                            |                   | Non-renal SLE              | sens.: 78%; spec.: 92%; PPV: 97%; NPV: 58%; OR = 39 | Ishizaki et al., 2015 [59] |
|                            |                   | Non-renal SLE              | sens.: 74%; spec.: 64%; PPV: 67%; NPV: 71%; OR = 5.0 | Martin et al., 2020 [60] |
|                            |                   | Active non-renal SLE       | sens.: 97%; spec.: 32%; PPV: 41%; NPV: 95% | Mok et al., 2016 [56] |
| C4 (low)                   | Serum/Plasma      | Non-renal SLE              | HR = 5.0                             | Liu et al., 2021 [54]       |
|                            |                   | Non-renal SLE              | sens.: 70%; spec.: 68%; PPV: 69%; NPV: 70%; OR = 5.1 | Martin et al., 2020 [56] |
| **Kidney disease-related markers** | |                  |                                      |                             |
| Albumin to globulin ratio (low) | Urine | Non-renal SLE | AUC = 0.65; sens.: 84%; spec.: 52%; HR = 5.5; HRadj = 7.0 | Liu et al., 2021 [54]      |
| Biomarker        | Sample          | Comparator       | Metrics                                                                 | References          |
|------------------|-----------------|------------------|-------------------------------------------------------------------------|---------------------|
| Creatinine (↑)   | Serum/Plasma    | Non-renal SLE    | AUC = 0.83; sens.: 75%; spec.: 76%; PPV: 86%; NPV: 61%                  | Yang et al., 2016   |
| Proteinuria (↑)  (>500 mg/24 h) | Urine    | Non-renal SLE    | AUC = 0.99                                                             | Jakiela et al., 2018 |
| Urea (↑)         | Serum/Plasma    | Non-renal SLE    | AUC = 0.82; sens.: 60%; spec.: 94%; PPV: 95%; NPV: 55%                 | Yang et al., 2016   |
| Uric acid (↑)    | Serum/Plasma    | Non-renal SLE    | AUC = 0.86; sens.: 78%; spec.: 79%; PPV: 70%; NPV: 75%                 | Calich et al., 2018 |
| Uric acid (↑)    | Serum/Plasma    | Non-renal SLE    | AUC = 0.81; sens.: 83%; spec.: 70%; PPV: 74%; NPV: 80%                 | Hafez et al., 2021  |
| Proteinuria (↑)  (>500 mg/24 h) | Urine    | Non-renal SLE    | AUC = 0.99                                                             | Jakiela et al., 2018 |
| Urea (↑)         | Serum/Plasma    | Non-renal SLE    | AUC = 0.82; sens.: 60%; spec.: 94%; PPV: 95%; NPV: 55%                 | Yang et al., 2016   |
| Uric acid (↑)    | Serum/Plasma    | Non-renal SLE    | AUC = 0.86; sens.: 78%; spec.: 79%; PPV: 70%; NPV: 75%                 | Calich et al., 2018 |
| Uric acid (↑)    | Serum/Plasma    | Non-renal SLE    | AUC = 0.81; sens.: 83%; spec.: 70%; PPV: 74%; NPV: 80%                 | Hafez et al., 2021  |
| APRIL (↑)        | Urine           | Active non-renal SLE | AUC = 0.78                                                             | Phatak et al., 2017 |
| BAFF (↑)         | Urine           | Active non-renal SLE | AUC = 0.83                                                             | Phatak et al., 2017 |
| CXCL4 (↑)        | Urine           | Active non-renal SLE | AUC = 0.64; sens.: 63%; spec.: 61%                                     | Mok et al., 2018    |
| MCP-1 (↑)        | Urine           | Non-renal SLE    | AUC = 0.73; sens.: 76%; spec.: 58%                                     | Gómez-Puerta et al.,|
|                 | Serum/Plasma    | Non-renal SLE    | AUC = 0.70                                                             | Barbado et al., 2012|
| TWEAK (↑)        | Urine           | Non-renal SLE    | AUC = 0.80; sens.: 100%; spec.: 67%                                    | Mirioglu et al., 2020|
|                 | Serum/Plasma    | Active non-renal SLE | AUC = 0.80; sens.: 80%; spec.: 80%                                    | Choe et al., 2016   |
|                 | Serum/Plasma    | Non-renal SLE    | AUC = 0.73; sens.: 83%; spec.: 93%; PPV: 94%; NPV: 95%                 | Elsaid et al., 2021 |
| VCAM-1 (↑)       | Urine           | Non-renal SLE    | AUC = 1.00; sens.: 100%; spec.: 100%                                   | Elsaid et al., 2021 |
| ALCAM (↑)        | Urine           | Active non-renal SLE | AUC = 0.75–0.96                                                        | Chalmers et al., 2022|
|                 | Urine           | Healthy controls | AUC = 0.82–0.96                                                        | Ding et al., 2020   |
| VCAM-1 (↑)       | Urine           | Active non-renal SLE | AUC = 0.73–0.92; sens.: 69%; spec.: 66%                               | Mok et al., 2018    |
|                 | Urine           | Healthy controls | AUC = 0.92                                                             | Singh et al., 2012  |
Table 1. Cont.

| Biomarker        | Sample      | Comparator                          | Metrics                      | References                          |
|------------------|-------------|-------------------------------------|------------------------------|-------------------------------------|
|                  |             | **Other proteins**                  |                              |                                     |
| Angiostatin (†)  | Urine       | Active non-renal SLE                 | AUC = 0.87; sens.: 80%; spec.: 82% | Mok et al., 2018 [64]               |
|                  |             | Healthy controls                     | AUC = 0.95                   | Wu et al., 2013 [69]                |
| Axl (†)          | Serum/Plasma| Active non-renal SLE; Inactive SLE   | sens.: 68%; spec.: 77%; PPV: 55%; NPV: 86% | Mok et al., 2016 [56]               |
| HE4 (†)          | Serum/Plasma| Non-renal SLE                        | AUC = 0.88; sens.: 77%; spec.: 91% | Yang et al., 2016 [23]              |
| IGFBP-2 (†)      | Serum/Plasma| CKD not LN                           | AUC = 0.65                   | Ding et al., 2016 [71]              |
| NGAL (†)         | Urine       | Active non-renal SLE; Inactive SLE   | sens.: 71%; spec.: 90%; PPV: 61%; NPV: 94% | Mok et al., 2016 [56]               |
|                  |             | Non-renal SLE                        | AUC = 0.99; sens.: 98%; spec.: 100% | Li et al., 2019 [42]                |
|                  |             | Non-renal SLE                        | AUC = 0.70; sens.: 67%; spec.: 63% | Gómez-Puerta et al., 2018 [41]     |
| sTNFRII (†)      | Serum/Plasma| Active non-renal SLE; Inactive SLE   | sens.: 41%; spec.: 81%; PPV: 48%; NPV: 86% | Mok et al., 2016 [56]               |
| TF (†)           | Urine       | Non-renal SLE                        | AUC = 0.81                   | Davies et al., 2021 [72]            |
| β2-MG (†)        | Urine       | Non-renal SLE                        | AUC = 0.85; sens.: 82%; spec.: 90% | Huang et al., 2019 [18]             |
| β2-MG (†)        | Urine       | Non-renal SLE                        | OR = 1.1                     | Choe et al., 2014 [74]              |
| miRNA-21 (†)     | Serum/Plasma| Non-renal SLE; Inactive LN           | AUC = 0.89; ORadj = 3.2       | Khoshmirsafa et al., 2019 [45]      |
|                  |             | Healthy controls                     | AUC = 0.91; sens.: 86%; spec.: 63%; PPV: 76%; NPV: 93% | Nakhjavani et al., 2019 [46]       |
| MP-CX3CR1 (†)    | Urine       | Non-renal SLE                        | AUC = 0.85; sens.: 63%; spec.: 86% | Burbano et al. [48]                |
| MP-HLADR (†)     | Urine       | Non-renal SLE                        | AUC = 0.97; sens.: 85%; spec.: 86% | Alves et al., 2021 [75]             |
| MP-HMGB1 (†)     | Urine       | Non-renal SLE                        | AUC = 0.99–1.00; sens.: 95–100%; spec.: 88% | Alves et al., 2021 [75]             |

Biomarkers are structured into subgroups (highlighted in bold) based on clinical/functional affinities. ALCAM: activated leukocyte cell adhesion molecule; Anti-dsDNA: anti-double-stranded DNA; Anti-ENO-1: anti-α-enolase 1; APRIL: a proliferation-inducing ligand; AUC: area under the curve; BAFF: B cell activating factor belonging to the TNF ligand superfamily; β2-MG: β2-microglobulin; CKD: chronic kidney disease; CXCL4: C-X-C motif chemokine ligand 4; CX3CR1: C-X3-C motif chemokine receptor 1; C3: complement component 3; C4: complement component 4; GNA: galantus nivalis agglutinin reaction; HE4: human epididymis protein 4; HMGB1: high mobility group box 1; HR: hazard ratio; HRadj: adjusted hazard ratio; icx: immune complexes; IGFBP-2: insulin-like growth factor binding protein 2; LN: lupus nephritis; MCP-1: monocyte chemoattractant protein 1; miRNA-21: microRNA-21; MP: microparticle; NGAL: neutrophil gelatinase associated lipocalin; NPV: negative predictive value; OR: odds ratio; PHACTR4: phosphatase and actin regulator 4; PPV: positive predictive value; P3H1: prolyl 3-hydroxylase 1; RGS12: regulator of G-protein signalling 12; sens.: sensitivity; SLE: systemic lupus erythematosus; spec.: specificity; sTNFRII: soluble tumour necrosis factor alpha receptor II; TF: transferrin; TWEAK: TNF-like weak inducer of apoptosis; VCAM-1: vascular cell adhesion molecule 1; (+): positivity; †: elevated. * This study evaluated IgG2 subclass antibodies.
A summary of the diagnostic biomarkers of LN as derived from the systematic search of the literature conducted herein is presented in Table 1.

3.2. Biomarkers of Disease Activity and Organ Damage

Cytokines and chemokines play a critical role in the development of LN, e.g., in the process of recruiting leukocytes and orchestrating the inflammatory response [12,76]. Serum IL-10 and IL-17 have been shown to exhibit satisfactory performances in discriminating between patients with active LN and patients with inactive LN and displayed a strong correlation with the disease activity parameters (see Table 2 for the detailed metrics) [61,77]. Several studies have investigated the potential of cytokines and chemokines as urinary biomarkers [11,61,78–80]. Using an innovative electrochemiluminescence-based multiplex panel, Stanley et al. identified and validated five selected urinary proteins (IL-7, IL-12p40, IL-15, thymus- and activation-regulated chemokine (TARC), and interferon-γ (IFN-γ) inducible protein-10/C-X-C Motif Chemokine Ligand 10 (IP-10/CXCL10)), which displayed diagnostic potential and strong correlations with the renal domain of Systemic Lupus Erythematosus Disease Activity Index (rSLEDAI) (r = 0.67–0.74; p < 0.001 for all) [78]. Of these, IP-10 was also investigated in other studies, which overall corroborated its association with renal SLE [12,61]. IP-10 is a member of the T-helper 1 lymphocyte chemokines; it is secreted in response to IFN stimulation and has been shown to be involved in the lymphocyte trafficking into afflicted organs in murine lupus models and SLE patients [81].

MCP-1 is another low molecular weight CC chemokine implicated in the recruitment of leukocytes and a mediator of inflammation and injury in LN [30,82]. MCP-1 expression is upregulated by several proinflammatory cytokines, including those belonging to the TNF superfamily. It has been shown that the TNFα/TNF receptor II (TNFRII) and TWEAK/Fn14 axes both induce the production of MCP-1, which, in turn, amplifies the inflammatory response [30,72,83]. This provides biological advocacy for a link between MCP-1 and other widely investigated biomarkers of LN, such as TWEAK and TNFRII [30,56,83]. MCP-1 was evaluated in several studies [11,30,41,65,84–90], and its value as a urinary marker of LN activity was further strengthened in a meta-analysis conducted by Xia et al., which reported a pooled sensitivity of 89% and pooled specificity of 63% (AUC = 0.90; pooled OR = 19.4) for distinguishing patients with active LN from patients with inactive LN [91]. Moreover, Urrego-Callejas et al. found that the urine levels of MCP-1 were significantly increased in patients with a National Institutes of Health (NIH) renal pathology chronicity index (CI) score ≥ 4, fibrous crescents, tubular atrophy, and interstitial fibrosis, underscoring the potential utility of this molecule as a less invasive, complementary biomarker of kidney damage in real-life clinical settings [92].

Angiogenesis-related proteins are emerging as a novel putative group of interest in LN. Large proteomic studies identified angiopoietin-like protein 4 (Angptl4) and angiostatin as useful urinary biomarkers for tracking renal disease activity and kidney pathology in patients with SLE [11,12,80]. Angptl4 is a cytokine implicated in multiple physiological and pathological vascular processes. Vanarsa et al. found that Angptl4 could differentiate between patients with active LN and active non-renal SLE, while it also strongly correlated with rSLEDAI (AUC = 0.96; r = 0.66; p < 0.001) [80]. Angiostatin is a 38-kDa peptide derived from the proteolytic cleavage of plasminogen and/or plasmin, with prominent inhibitory effects on angiogenesis and endothelial cell proliferation [93,94]. Several enzymes, including plasmin, plasminogen activators, and other proteinases, e.g., matrix metalloproteinase (MMP)-2, MMP3, MMP-7, and MMP-9, have been reported to mediate the production of angiostatin and angiostatin-like molecules [93]. Angiostatin demonstrated an excellent association with LN in different studies (AUC = 0.95–0.99; p < 0.001 for all) [12,69,95]. Moreover, angiostatin has been reported to correlate with several disease activity and organ damage measures, including rSLEDAI, SLEDAI, the NIH renal histology activity index (AI), and NIH renal pathology CI (r = 0.33–0.52, r = 0.36, r = 0.97, and r = 0.52, respectively; p < 0.001 for all), thus emerging as a promising versatile marker with potential value in LN surveillance [69,95].
LN has been associated with a hypercoagulability state as a result of the inflammatory response, and renal thrombotic angiopathy is a feature of severe kidney disease activity in patients with SLE [96]. Qin et al. conducted an exploratory study to evaluate the potential usefulness of haemostasis-related proteins as urinary markers of LN [97]. Among the proteins assessed, i.e., the d-dimer, tissue factor, tissue factor pathway inhibitor (TFPI), and plasmin and urinary plasmin outperformed the others, showing the strongest correlation with rSLEDAI and the Systemic Lupus International Collaborating Clinics Renal Activity Score (SLICC-RAS) (r = 0.50 and r = 0.58, respectively; p < 0.001), as well as the ability to distinguish active from inactive LN (AUC = 0.86; p < 0.001) [97]. Although it still is poorly understood whether urinary plasmin derives from serum plasmin or originates from kidney tissue, it has been demonstrated that the renal expression of its autocatalytic product, angiostatin, is increased in patients with LN [69,97]. In addition, macrophages are likely to contribute to chronic kidney damage and fibrous crescent formation by means of the expression of procoagulant factors [92,96], thus reinforcing the hypothesis of the renal origin of urinary plasmin.

Cell adhesion molecules (CAMs) are key mediators of the inflammatory process and play a critical role in leukocyte transmigration across the endothelium within affected tissues by interacting with integrins expressed on the surfaces of leukocytes [98]. Among them, urinary vascular cell adhesion molecule 1 (VCAM-1) and activated leukocyte cell adhesion molecule (ALCAM) are broadly validated LN biomarkers [11,66–68,87,95,99,100], both displaying a good ability to distinguish patients with active LN from patients with inactive LN or non-renal SLE, and correlate with markers of clinical renal disease activity (see Table 2 for the detailed metrics). Urinary VCAM-1 holds promise as a non-invasive predictor of underlying active renal disease; a strong association between urinary VCAM-1 and NIH renal histology AI was displayed in two separate studies (r = 0.42 and r = 0.97; p = 0.05 and p < 0.001, respectively) [66,95]. Moreover, the urine levels of VCAM-1 were found to correlate with NIH renal pathology CI and the chronic kidney disease (CKD) stages (r = 0.30 and r = 0.39–0.50; p < 0.05 for all), suggesting a role as a marker of organ damage [87,99]. Additionally, urinary ALCAM demonstrated a good ability to differentiate between proliferative and membranous LN (AUC = 0.81; p < 0.001), outperforming the ability of traditional markers, i.e., C3, C4, anti-dsDNA, and 24-h urinary protein excretion, in a recent study by Ding et al. [68].

CD163 is a scavenger receptor expressed on the surface of alternatively activated M2c macrophages [101]. Urinary soluble CD163 (sCD163) originates from the extracellular portion of its membrane-bound counterpart upon cleavage by MMPs during inflammation [102]. Soluble CD163 is considered a yardstick of glomerular infiltration of CD163+ M2 macrophages, which, in turn, is linked to LN histological and clinical renal activity [102,103]. While having a physiological function in wound healing and tissue repair, this subset of macrophages was also found to be increased in areas of glomerular and tubular injury and may be a major driver of crescent formation and interstitial fibrosis [101,103]. When evaluated in multiple independent cohorts [79,101–103], urinary sCD163 could discriminate between patients with active LN from patients with inactive LN or non-renal SLE, suggesting a potential use in monitoring LN disease activity (see Tables 2 and 3 for the detailed metrics). In addition, in a study by Endo et al., urinary sCD163 was shown to be a reliable predictor of renal proliferative disease in patients with LN (AUC = 0.83–0.89; sens.: 83%; spec.: 86%) [102]. Similar results were obtained in another study where urinary sCD163 outperformed the conventional markers, i.e., anti-dsDNA, C3, C4, and uPCR, in distinguishing proliferative from non-proliferative LN (AUC = 0.89; p < 0.001) [103].
Table 2. Performances of selected biomarkers of clinical disease activity in LN.

| Biomarker            | Sample                  | Comparator                  | Disease activity                          | Metrics                                      | References |
|----------------------|-------------------------|-----------------------------|-------------------------------------------|----------------------------------------------|------------|
| **Autoantibodies**   |                         |                             |                                           |                                              |            |
| Anti-C1q (+)         | Serum/Plasma            | Inactive LN; proteinuria; SLEDAI | AUC = 0.76; sens.: 72%; spec.: 55%; r = 0.28 (proteinuria); r = 0.28 (SLEDAI) | Gómez-Puerta et al., 2018 [41]            |            |
|                      |                         | Inactive LN; active urinary sediment | AUC = 0.73; sens.: 63%; spec.: 75%; PPV: 69%; NPV: 67%; OR = 5.1 | Kianmehr et al., 2021 [105]             |            |
|                      |                         | Inactive LN; proteinuria; active urinary sediment | OR = 8.4 | Sjowall et al., 2018 [50] |            |
|                      |                         | SLE with no renal flares; renal flares | sens.: 70%; spec.: 44% | Birmingham et al., 2016 [51] |            |
|                      |                         | SLE with no renal flares; renal flares | sens.: 75%; spec.: 69%; PPV: 35%; NPV: 93%; HRadj = 1.1 | Fatemi et al., 2016 [106] |            |
|                      |                         | Inactive LN; proteinuria; SLEDAI | AUC = 0.83; sens.: 71%; spec.: 88% | Jakiela et al., 2018 [61] |            |
|                      |                         | Inactive LN; proteinuria; active urinary sediment; SLEDAI | AUC = 0.70; sens.: 71%; spec.: 63%; PPV: 63%; NPV: 71%; OR = 4.2 r = 0.23 (SLEDAI) | Kianmehr et al., 2021 [105] |            |
|                      |                         | Inactive LN; proteinuria; active urinary sediment | OR = 4.8 | Sjowall et al., 2018 [50] |            |
|                      |                         | SLE with no renal flares; renal flares | AUC = 0.85; sens.: 88%; spec.: 83%; PPV: 43%; NPV: 97%; HR = 21.7 | Fasano et al., 2020 [107] |            |
|                      |                         | SLE with no renal flares; renal flares | AUC = 0.63; sens.: 46%; spec.: 80%; PPV: 44%; NPV: 81% | Yap et al., 2016 [108] |            |
| **Complements**      |                         |                             |                                           |                                              |            |
| C3 (low)             | Serum/Plasma            | Inactive LN; proteinuria; SLEDAI | AUC = 0.88; sens.: 100%; spec.: 65% | Jakiela et al., 2018 [61] |            |
|                      |                         | N/A                         | SLEDAI r = −0.99 (SLEDAI) | Selvaraja et al., 2019 [109] |            |
|                      |                         | Active non-renal SLE; renal flares | sens.: 70%; spec.: 59%; OR = 2.5 | Ruchakorn et al., 2019 [110] |            |
|                      |                         | SLE with no renal flares; renal flares | AUC = 0.76; sens.: 100%; spec.: 51%; PPV: 23%; NPV: 100%; HR = 6.0 | Fasano et al., 2020 [107] |            |
|                      |                         | N/A                         | SLEDAI r = −0.83 (SLEDAI) | Selvaraja et al., 2019 [109] |            |
|                      |                         | Inactive LN; proteinuria; SLEDAI | AUC = 0.88; sens.: 81%; spec.: 88% | Jakiela et al., 2018 [61] |            |
|                      |                         | SLE with no renal flares; renal flares | AUC = 0.82; sens.: 100%; spec.: 62%; PPV: 28%; NPV: 100%; HR = 5.5 | Fasano et al., 2020 [107] |            |
|                      |                         | SLE with no renal flares; renal flares | ORadj = 5.6 | Buyon et al., 2017 [111] |            |
Table 2. Cont.

| Biomarker                      | Sample          | Comparator                                        | Disease activity                                      | Metrics                  | References               |
|-------------------------------|-----------------|---------------------------------------------------|------------------------------------------------------|--------------------------|--------------------------|
| **Kidney disease-related markers** |                 |                                                   |                                                      |                          |                          |
| Proteinuria (†) (>500 mg/24 h) | Urine           | Inactive LN: proteinuria; active urinary sediment | AUC = 0.94                                            |                          | Dolff et al., 2013 [112] |
|                               |                 | Inactive LN: proteinuria; SLEDAI                   | AUC = 0.99; sens.: 88%; spec.: 100%                  |                          | Jakiela et al., 2018 [61]|
|                               |                 | SLE with no renal flares: renal flares            | PPV: 43%; NPV: 85%; HR(adj) = 1.1                    |                          | Fatemi et al., 2016 [106]|
| WBC (†)                       | Urine           | Inactive LN: proteinuria; SLEDAI                   | AUC = 0.75; sens.: 71%; spec.: 73%                   |                          | Jakiela et al., 2018 [61]|
| RBC (†)                       | Urine           | Inactive LN: proteinuria; SLEDAI                   | AUC = 0.92; sens.: 77%; spec.: 100%                  |                          | Jakiela et al., 2018 [61]|
| Granular casts (+)            | Urine           | Inactive LN: proteinuria; SLEDAI                   | AUC = 0.91; sens.: 82%; spec.: 91%                   |                          | Jakiela et al., 2018 [61]|
| **Cytokines/chemokines**      |                 |                                                   |                                                      |                          |                          |
| IL-10 (†)                     | Serum/Plasma    | Inactive LN: proteinuria; SLEDAI                   | AUC = 0.87; sens.: 71%; spec.: 85%                   |                          | Jakiela et al., 2018 [61]|
|                               |                 | N/A                                               | r = 0.98 (SLEDAI)                                     |                          | Selvaraja et al., 2019 [109]|
| IL-17 (†)                     | Serum/Plasma    | Inactive LN: SLEDAI                               | AUC = 0.91; r = 0.63 (SLEDAI)                         |                          | Dedong et al., 2019 [77]  |
|                               |                 | Inactive LN: BILAG renal score                     | AUC = 0.81; r = 0.26 (BILAG renal score)             |                          | Nordin et al., 2019 [113]|
| IL-7 (†)                      |                 |                                                   | AUC = 0.92; sens.: 84%; spec.: 95%; PPV: 95%; NPV: 84%; r = 0.70 (rSLEDAI) |                          | Stanley et al., 2019 [78]|
| IL-12 p40 (†)                 | Urine           | Inactive SLE: rSLEDAI                             | AUC = 0.93; sens.: 87%; spec.: 100%; PPV: 100%; NPV: 88%; r = 0.67 (rSLEDAI) |                          | Stanley et al., 2019 [78]|
| IL-15 (†)                     |                 | Inactive LN: Non-renal SLE: rSLEDAI               | AUC = 0.70; r = 0.35 (rSLEDAI)                        |                          | Liu et al., 2020 [87]     |
|                               |                 | Inactive LN: SLEDAI                               | AUC = 0.76; sens.: 81%; spec.: 85%                   |                          | Bona et al., 2020 [86]    |
|                               |                 | Inactive SLE: rSLEDAI                             | AUC = 0.79; sens.: 93%; spec.: 68%; PPV: 93%; NPV: 68% |                          | Stanley et al., 2020 [11]|
| MCP-1 (†)                     | Urine           | Inactive LN: proteinuria; rSLEDAI                  | AUC = 1.00; sens.: 100%; spec.: 100%; PPV: 100%; NPV: 100%; r = 0.84 (proteinuria); r = 0.92 (rSLEDAI) |                          | Elsavid et al., 2021 [30]|
|                               |                 | Inactive LN: SLEDAI-2K                            | AUC = 0.81; sens.: 50%; spec.: 90%; r = 0.39 (SLEDAI-2K) |                          | Rosa et al., 2012 [84]    |
|                               |                 | Inactive LN: proteinuria; SLEDAI                  | AUC = 0.71; sens.: 70%; spec.: 58%; r = 0.47 (proteinuria); r = 0.33 (SLEDAI) |                          | Gómez-Puerta et al., 2018 [41]|
|                               |                 | Inactive LN: N/A                                  | AUC = 0.90; sens.: 89%; spec.: 63%; OR = 19.4        |                          | Xia et al., 2020 [91]     |
| Biomarker         | Sample  | Comparator        | Disease activity | Metrics                                      | References                                      |
|------------------|---------|-------------------|------------------|----------------------------------------------|------------------------------------------------|
| IP-10/CXCL10 (†) | Urine   | Inactive SLE      | rSLEDAI          | AUC = 0.94; sens.: 87–88%; spec.: 81–100%; PPV: 100%; NPV: 88%; r = 0.67–0.74 (rSLEDAI) | Stanley et al., 2019 [78]                      |
|                  |         | Inactive LN       | proteinuria; SLEDAI | AUC = 0.93; sens.: 88%; spec.: 81% | Jakiela et al., 2018 [61]                      |
| Healthy controls | N/A     |                   |                  | AUC = 0.92 | Zhang et al., 2020 [12]                      |
| PF-4 (†)         | Urine   | Inactive SLE      | rSLEDAI          | AUC = 0.71–0.88; sens.: 54–93%; spec.: 79–96%; PPV: 82–94%; NPV: 77–88% | Stanley et al., 2020 [11]                      |
| TARC (†)         | Urine   | Inactive SLE      | rSLEDAI          | AUC = 0.91; sens.: 78%; spec.: 92%; PPV: 91%; NPV: 80%; r = 0.70 (rSLEDAI) | Stanley et al., 2019 [78]                      |
| TGFβ1 (†)        | Urine   | Active non-renal SLE | proteinuria | r = 0.51 (proteinuria) | Fava et al., 2022 [79]                         |
|                  |         | Active non-renal SLE | rSLEDAI | AUC = 0.78; r = 0.37 (rSLEDAI) | Vanarsa et al., 2020 [80]                      |
| TWEAK (†)        | Urine   | Inactive LN       | proteinuria; rSLEDAI | AUC = 1.00; sens.: 100%; spec.: 100%; PPV: 100%; NPV: 100%; r = 0.84 (proteinuria); r = 0.89 (rSLEDAI) | Elsaid et al., 2021 [30]                       |
|                 |         |                   |                  | r = 0.61 (proteinuria) | Reyes-Martínez et al., 2018 [27]               |
| Angiogenesis-related molecules |           |                   |                  |                                                |                                                |
| Angptl4 (†)      | Urine   | Active non-renal SLE | rSLEDAI | AUC = 0.96; r = 0.66 | Vanarsa et al., 2020 [80]                      |
|                 |         | Healthy controls  | N/A              | AUC = 0.92 | Wu et al., 2016 [13]                         |
|                  | Serum/Plasma | Inactive LN     | SLEDAI           | AUC = 0.83 | Wu et al., 2016 [13]                         |
| Angiostatin (†)  | Urine   | Inactive LN       | rSLEDAI          | AUC = 0.99; sens.: 83%; spec.: 100%; r = 0.33 (rSLEDAI) | Soliman et al., 2017 [95]                      |
|                 |         | Healthy controls  | N/A              | AUC = 0.97 | Zhang et al., 2020 [12]                      |
|                  |         | Inactive SLE      | rSLEDAI; SLEDAI; SLICC-RAS | AUC = 0.83; r = 0.52 (rSLEDAI); r = 0.36 (SLEDAI); r = 0.68 (SLICC-RAS) | Wu et al., 2013 [69]                           |
| Haemostasis-related molecules |           |                   |                  |                                                |                                                |
| Plasmin (†)      | Inactive LN | rSLEDAI         |                  | AUC = 0.86; sens.: 100%; spec.: 70%; PPV: 96%; NPV: 50%; r = 0.50 (rSLEDAI); r = 0.58 (SLICC-RAS) | Qin et al., 2019 [97]                          |
| Tissue Factor (†) | Urine   | Inactive LN       | rSLEDAI; SLICC-RAS | AUC = 0.74; sens.: 61%; spec.: 85%; PPV: 90%; NPV: 35%; r = 0.33 (rSLEDAI); r = 0.38 (SLICC-RAS) | Qin et al., 2019 [97]                          |
| TFPI (†)         | Inactive SLE | rSLEDAI         |                  | AUC = 0.71–0.88; sens.: 57–80%; spec.: 84–89%; PPV: 73–89%; NPV: 73–82% | Stanley et al., 2020 [11]                      |
| Biomarker     | Sample      | Comparator     | Disease activity | Metrics                      | References                  |
|--------------|-------------|----------------|------------------|------------------------------|-----------------------------|
| **Cell adhesion molecules**                      |             |                |                  |                              |                             |
| ALCAM (†)    | Urine       | Inactive SLE   | rSLEDAI          | AUC = 0.84%;                | Chalmers et al., 2022 [67]  |
|              |             |                |                  | sens.: 79–94%;              |                              |
|              |             |                |                  | PPV: 86–91%;                |                              |
|              |             |                |                  | spec.: 90–92%               |                              |
|              |             |                |                  | r = 0.35–0.41 (rSLEDAI)     |                             |
| ICAM-1 (†)   | Urine       | Inactive LN    | proteinuria;     | AUC = 0.97;                  | Wang et al., 2018 [114]     |
|              |             |                | active urinary    | sens.: 93–98%;              |                              |
|              |             |                | sediment         | spec.: 81–86%               |                              |
| NCAM-1 (†)   | Urine       | Inactive LN    | proteinuria;     | AUC = 0.88;                  | Wang et al., 2018 [114]     |
|              |             |                | active urinary    | sens.: 82%;                 |                              |
|              |             |                | sediment         | spec.: 87%                  |                              |
| Serum/       | Inactive LN | rSLEDAI-2K;    |                  | AUC = 0.86;                  | Yu et al., 2021 [115]        |
| Plasma       |             | SLEDAI-2K      |                  | sens.: 69%;                 |                              |
|              |             |                |                  | spec.: 90%                   |                              |
|              |             |                |                  | r = 0.61 (rSLEDAI-2K);      |                              |
|              |             |                |                  | r = 0.62 (SLEDAI-2K)        |                              |
| VCAM-1 (†)   | Urine       | Inactive SLE   | rSLEDAI          | AUC = 0.84–0.87;             | Stanley et al., 2020 [11]   |
|              |             |                |                  | sens.: 92–96%;              |                              |
|              |             |                |                  | spec.: 65–74%;              |                              |
|              |             |                |                  | PPV: 93–95%;                |                              |
|              |             |                |                  | spec.: 87%                  |                              |
|              |             |                |                  | r = 0.32 (rSLEDAI);         |                              |
|              |             |                |                  | r = 0.32 (SLEDAI)           |                              |
| Other proteins                                      |             |                |                  |                              |                             |
| Axl (†)      | Serum/      | Inactive LN    | SLEDAI           | AUC = 0.87                   | Wu et al., 2016 [13]         |
|              | Plasma      |                |                  |                              |                             |
| Calpastatin (†) | Urine     | Inactive SLE   | rSLEDAI          | AUC = 0.72–0.75;             | Stanley et al., 2020 [11]   |
|              |             |                |                  | sens.: 50–66%;              |                              |
|              |             |                |                  | spec.: 78–100%;             |                              |
|              |             |                |                  | PPV: 75–82%;                |                              |
|              |             |                |                  | spec.: 78%                  |                              |
| CD163 (†)    | Urine       | Inactive LN    | N/A              | AUC = 0.98–0.99;             | Mejia-Vilet et al., 2020 [101]|
|              |             |                |                  | sens.: 97%;                 |                              |
|              |             |                |                  | spec.: 94%                  |                              |
|              |             |                |                  | r = 0.45–0.75 (rSLEDAI)     | Zhang et al., 2020 [103]     |
| Ferritin (†) | Serum/      | Inactive LN    | SLEDAI           | AUC = 0.84                   | Wu et al., 2016 [13]         |
|              | Plasma      |                |                  |                              |                             |
| FOLR2 (†)    | Urine       | Active non-renal SLE | rSLEDAI       | AUC = 0.73;                  | Vanarsa et al., 2020 [80]   |
|              |             |                |                  | r = 0.62 (rSLEDAI)          |                             |
| Hemopexin (†) | Urine      | Inactive SLE   | rSLEDAI          | AUC = 0.73–0.80;             | Stanley et al., 2020 [11]   |
|              |             |                |                  | sens.: 85–100%;             |                             |
|              |             |                |                  | spec.: 56–99%;              |                             |
|              |             |                |                  | PPV: 79–100%;               |                             |
|              |             |                |                  | spec.: 57–70%               |                             |
Table 2. Cont.

| Biomarker       | Sample                        | Comparator | Disease activity | Metrics                                                                 | References                  |
|-----------------|-------------------------------|------------|------------------|--------------------------------------------------------------------------|----------------------------|
| IGFBP-2 (†)     | Serum/Plasma                  | N/A        | rSLEDAI          | r = 0.41 (rSLEDAI)                                                       | Ding et al., 2016 [71]      |
| L-selectin (†)  | Urine                         | Active non-renal SLE | rSLEDAI          | AUC = 0.86; r = 0.73 (rSLEDAI)                                            | Vanarsa et al., 2020 [80]  |
| NGAL (†)        | Urine                         | Active non-renal SLE | rSLEDAI          | AUC = 0.83; sens.: 89%; spec.: 67%                                       | Alharazy et al., 2013 [116]|
| PDGFRB (†)      | Urine                         | Inactive SLE | rSLEDAI          | AUC = 0.64–0.75; sens.: 50–56%; spec.: 79–91%; PPV: 68–87%; NPV: 64–68% | Stanley et al., 2020 [11]  |
| Peroxiredoxin 6 (†) | Urine                         | Stable LN   | Proteinuria; SLEDAI | AUC = 0.67; sens.: 60%; spec.: 100%; PPV: 100%; NPV: 73%; r = 0.57 (rSLEDAI); r = 0.62 (SLEDAI) | Wu et al., 2016 [117]      |
| Properdin (†)   | Urine                         | Stable LN   | Proteinuria; SLEDAI | AUC = 0.90; sens.: 65%; spec.: 99%; PPV: 98%; NPV: 74%; r = 0.59 (rSLEDAI); r = 0.58 (SLEDAI) | Stanley et al., 2020 [11]  |
| RBP4 (†)        | Urine                         | Active SLE   | Proteinuria; flare | AUC = 0.67; sens.: 93%; spec.: 67%; HR = 9.5                            | Go et al., 2018 [118]       |
| SDC-1 (†)       | Serum/Plasma                  | Inactive LN | proteinuria; rSLEDAI-2K; SLEDAI-2K | AUC = 0.91; sens.: 85%; spec.: 86%; r = 0.57 (proteinuria); r = 0.68 (rSLEDAI-2K); r = 0.54 (SLEDAI-2K) | Yu et al., 2021 [120]      |
| sTNFRII (†)     | Serum/Plasma                  | Non-renal SLE | rSLEDAI; rLAI    | AUC = 0.77; r = 0.30 (rSLEDAI); r = 0.39 (rLAI)                           | Smith et al., 2019 [122]   |
|                 |                               | Inactive LN | N/A              | AUC = 0.81                                                                | Wu et al., 2016 [13]        |
### Table 2. Cont.

| Biomarker | Sample | Comparator | Disease activity | Metrics | References |
|-----------|--------|------------|------------------|---------|------------|
| TSP1 (†) | Urine  | Active non-renal SLE | rSLEDAI | AUC = 0.72 | Vanarsa et al., 2020 [80] |
| TTP1 (†) | Urine  | Active non-renal SLE | rSLEDAI | AUC = 0.84 | Vanarsa et al., 2020 [80] |

#### Microparticles

| Biomarker | Sample | Comparator | Disease activity | Metrics | References |
|-----------|--------|------------|------------------|---------|------------|
| MP-HMGB1+ (‡) | Urine | Inactive LN | N/A | AUC = 0.83; sens.: 55%; spec.: 93% | Burbano et al., 2019 [48] |

**Biomarkers are structured into subgroups (highlighted in bold) based on clinical/functional affinities.**

- ALCAM: activated leukocyte cell adhesion molecule
- Angptl4: angiopoietin-like protein 4
- Anti-dsDNA: anti-double-stranded DNA
- AUC: area under the curve
- BILAG: British Isles Lupus Assessment Group
- CCL: C-C motif chemokine ligand
- Cr: creatinine
- CXCL: C-X-C motif chemokine ligand
- C3: complement component 3
- C4: complement component 4
- ECLAM: European Consensus Lupus Activity Measurement
- FOLR2: folate receptor beta
- HMGB1: high mobility group box 1
- HR: hazard ratio
- HR_adj: adjusted hazard ratio
- ICAM-1: intercellular cell adhesion molecule 1
- ICAM-2: intercellular cell adhesion molecule 2
- IP-10/CXCL10: interferon gamma inducible protein-10/C-X-C motif chemokine ligand 10
- LN: lupus nephritis
- MCP-1: monocyte chemoattractant protein 1
- MP: microparticle
- N/A: not applicable
- NCAM-1: neural cell adhesion molecule 1
- NGAL: neutrophil gelatinase associated lipocalin
- NPV: negative predictive value
- OR: odds ratio
- PDGFRβ: platelet-derived growth factor receptor beta
- PF-4: platelet factor 4
- PPV: positive predictive value
- PTEC-binding IgG: proximal renal tubular epithelial cell-binding immunoglobulin G
- r: correlation coefficient
- RBC: red blood cells
- RBP4: retinol binding protein 4
- rLAI: renal Lupus Activity Index
- rSLEDAI: renal SLEDAI
- rSLEDAI-2K: renal SLEDAI 2000
- SDC-1: syndecan 1
- sens.: sensitivity
- sIL-7R: soluble interleukin 7 receptor
- SLAM-R: Systemic Lupus Activity Measure Revised
- SLIC: Systemic Lupus International Collaborating Clinics
- SLICC-RAS: Systemic Lupus International Collaborating Clinics Renal Activity Score
- spec.: specificity
- sTNFRII: soluble tumour necrosis factor alpha receptor II
- TARC: thymus- and activation-regulated chemokine
- TFPI: tissue factor pathway inhibitor
- TGFβ1: transforming growth factor β1
- TSP1: thrombospondin 1
- TTP1: tripeptidyl-peptidase 1
- TWEAK: TNF-like weak inducer of apoptosis
- uPCR: urine protein to creatinine ratio
- VCAM-1: vascular cell adhesion molecule 1
- WBC: white blood cells
- (+): positivity
- †: elevated

---

### Table 3. Performances of selected biomarkers of histological disease activity.

| Biomarker | Sample | Comparator | Disease activity | Metrics | References |
|-----------|--------|------------|------------------|---------|------------|
| Complement | | | | | |
| C1q (low) | Serum/Plasma | N/A | AI | r = −0.33 (AI) | Tan et al., 2013 [123] |
| C3 (low) | Serum/Plasma | membranous LN | proliferative LN | AUC = 0.77; sens.: 75%; spec.: 74%; PPV: 92%; NPV: 44% | Ding et al., 2020 [68] |

**Kidney disease-related markers**

| Biomarker | Sample | Comparator | Disease activity | Metrics | References |
|-----------|--------|------------|------------------|---------|------------|
| Proteinuria (†) (>500 mg/24 h) | Urine | Inactive LN | proliferative LN | AUC = 0.91; sens.: 89%; spec.: 85% | Enghard et al., 2014 [124] |

#### Cytokines/chemokines

| Biomarker | Sample | Comparator | Disease activity | Metrics | References |
|-----------|--------|------------|------------------|---------|------------|
| IL-17 (†) | Serum/Plasma | N/A | AI | r = 0.52 (AI) | Dedong et al., 2019 [77] |
| IL-16 (†) | Urine | N/A | AI | r = 0.59–0.73 (AI) | Fava et al., 2022 [79] |
| MCP-1 (†) | Urine | Non-proliferative LN | proliferative LN | AUC = 0.64–0.78 | Endo et al., 2016 [102] |
| TGFβ1 (†) | Urine | N/A | AI | r = 0.65 (AI) | Fava et al., 2022 [79] |

#### Angiogenesis-related molecules

| Biomarker | Sample | Comparator | Disease activity | Metrics | References |
|-----------|--------|------------|------------------|---------|------------|
| Angiostatin (†) | Urine | N/A | AI | r = 0.93 (AI) | Soliman et al., 2017 [95] |

#### Cell adhesion molecules

| Biomarker | Sample | Comparator | Disease activity | Metrics | References |
|-----------|--------|------------|------------------|---------|------------|
| ALCAM (†) | Urine | Membranous LN | proliferative LN | AUC = 0.81; sens.: 78%; spec.: 81%; PPV: 94%; NPV: 52% | Ding et al., 2020 [68] |
| VCAM-1 (†) | Urine | N/A | AI | r = 0.42 (AI) | Singh et al., 2012 [66] |
| | | N/A | AI | r = 0.97 (AI) | Soliman et al., 2017 [95] |
Table 3. Cont.

| Biomarker | Sample | Comparator | Disease activity | Metrics | References |
|-----------|--------|------------|------------------|---------|------------|
| **Other proteins** | | | | | |
| CD163 (†) | Urine | N/A | AI | $r = 0.48-0.59$ (AI) | Mejia-Vilet et al., 2020 [101] |
| | | Non-proliferative LN | proliferative LN | $AUC = 0.83-0.89$; sens.: 83%; spec.: 86% | Endo et al., 2016 [102] |
| | | N/A | AI | $r = 0.41$ (AI) | |
| | | Non-proliferative LN | proliferative LN | $AUC = 0.89$ | Zhang et al., 2020 [103] |
| SDC-1 (†) | Serum/Plasma | N/A | AI | $r = 0.67$ (AI) | Fava et al., 2022 [79] |
| sTNFRII (†) | Serum/Plasma | N/A | AI | $r = 0.40$ (AI) | Wu et al., 2016 [13] |

### Renal tissue markers

- **CSF-1 (†)** Kidney biopsy | Non-renal SLE | AI | $r = 0.46$ | Menke et al., 2015 [125]

Biomarkers are structured into subgroups (highlighted in bold) based on clinical/functional affinities. AI: National Institutes of Health (NIH) renal histology activity index; ALCAM: activated leukocyte cell adhesion molecule; AUC: area under the curve; CSF-1: colony stimulating factor 1; C3: complement component 3; C1q: complement component 1q; LN: lupus nephritis; MCP-1: monocyte chemoattractant protein 1; N/A: not applicable; NPV: negative predictive value; PPV: positive predictive value; r: correlation coefficient; $r_{adj}$: adjusted correlation coefficient; SDC-1: syndecan 1; sens.: sensitivity; spec.: specificity; sTNFRII: soluble tumour necrosis factor alpha receptor II; TGF$\beta$1: transforming growth factor $\beta$1; VCAM-1: vascular cell adhesion molecule 1; †: elevated.

Furthermore, along with their diagnostic utility, the levels of TWEAK and NGAL were also found to resemble clinical disease activity in patients with LN, placing these molecules among the candidate biomarkers for LN surveillance (Table 2).

The metrics of the selected biomarkers of clinical disease activity, histological disease activity, and organ damage in LN, as determined from the present systematic literature review, are provided in Table 2, Table 3, and Table 4, respectively.

Table 4. Performances of selected biomarkers of organ damage in LN.

| Biomarker | Sample | Comparator | Organ Damage | Metrics | References |
|-----------|--------|------------|--------------|---------|------------|
| **Autoantibodies** | | | | | |
| Anti-dsDNA (+) | Serum/Plasma | Non-CKD SLE | CKD stages | $OR_{adj} = 2.0$ | Barnado et al., 2019 [57] |
| **Kidney disease-related markers** | | | | | |
| Urea (†) (>10.25 mmol/L) | Serum/Plasma | Non-CKD LN | CKD stages | $AUC = 0.91$; sens.: 85%; spec.: 83%; PPV: 82%; NPV: 86% | Yang et al., 2016 [23] |
| Angiostatin (†) | Urine | N/A | CI | $r = 0.52$ | Wu et al., 2013 [69] |
| IGFBP-2 (†) | Serum/Plasma | N/A | CI | $r = 0.58$ | Ding et al., 2016 [71] |
| IGFBP-4 (†) | Serum/Plasma | N/A | CI; eGFR | $r = 0.71$; $r = -0.62$ | Wu et al., 2016 [126] |
| Resistin (†) | Serum/Plasma | N/A | creatinine; BUN | $r = 0.45$; $r = 0.54$ | Hutcheson et al., 2015 [127] |
| sTNFRII (†) | Serum/Plasma | N/A | CI | $r = 0.34-0.43$ | Parodis et al., 2017 [83] |

### Other proteins

- **Angiostatin (†)** Urine | N/A | CI | $r = 0.57$; $r = -0.50$ | Wu et al., 2016 [13] |
Table 4. Cont.

| Biomarker | Sample | Comparator | Organ Damage | Metrics | References |
|-----------|--------|------------|--------------|---------|------------|
| VCAM-1 (↑) | Urine | N/A | CKD stages | r = 0.39–0.50 | Parodis et al., 2020 [99] |
| | N/A | CI | r = 0.30 | Liu et al., 2020 [87] |

Renal tissue markers

| Biomarker | Sample | Comparator | Organ Damage | Metrics | References |
|-----------|--------|------------|--------------|---------|------------|
| Periostin (↑) | Kidney biopsy | N/A | CI; creatinine; BUN; eGFR | r = 0.59; r = 0.43; r = 0.31; r = −0.45 | Wantanasiri et al., 2015 [128] |

Biomarkers are structured into subgroups (highlighted in bold) based on clinical/functional affinities. Anti-dsDNA: anti-double-stranded DNA; AUC: area under the curve; BUN: blood urea nitrogen; CKD: chronic kidney disease; CI: NIH renal pathology chronicity index; eGFR: estimated glomerular filtration rate; IGFBP-2: insulin-like growth factor binding protein 2; IGFBP-4: insulin-like growth factor binding protein 4; LN: lupus nephritis; N/A: not applicable; NPV: negative predictive value; OR: odds ratio; OR_{adj}: adjusted odds ratio; PPV: positive predictive value; r: correlation coefficient; sens.: sensitivity; SLE: systemic lupus erythematosus; spec.: specificity; sTNFRII: soluble tumour necrosis factor receptor II; VCAM-1: vascular cell adhesion molecule 1; (+): positivity; ↑: elevated.

3.3. Biomarkers of Response to Therapy

Axl is a tyrosine kinase receptor, which has been suggested to be involved in LN by means of mediating mesangial proliferation through interaction with its ligand, Gas6 [129]. In addition, when bound to Gas6, Axl plays an important immunoregulatory role on innate immune cells and promotes the clearance of apoptotic bodies, a process that is well-known to be impaired in SLE [130]. A soluble form of Axl (sAxl) is obtained from the ectodomain of Axl, which is present on the surfaces of macrophages and B cells, through proteolytic cleavage [56]. The shedding of sAxl, enhanced by inflammation, may be instrumental in LN pathogenesis by dysregulating physiological Axl/Gas6 signalling. Specifically, sAxl may act as a decoy receptor and block Gas6-induced anti-inflammatory effects on immune cells [131]. There is evidence of a correlation between serum sAxl and SLE activity [132], and in a recent discovery study, sAxl could differentiate between active LN and non-renal SLE [13]. In a prospective cohort of biopsy-proven LN, lower post-treatment serum levels of sAxl were observed in clinical responders but not in clinical non-responders and predicted good long-term renal outcomes [131]. Additionally, in the same work, high baseline levels of sAxl were strongly associated with the histological response to therapy based on post-treatment repeat biopsies after adjustment for the confounding factors (OR$_{adj}$ = 9.3; p = 0.02) [131].

A B-cell-activating factor belonging to the TNF ligand superfamily (BAFF) is a cytokine member of the TNF family that is believed to have a key role in LN pathogenesis and has also been suggested as a promising biomarker for LN [133]. The importance of BAFF in LN was recently corroborated with approval by the regulatory authorities of the BAFF inhibitor belimumab for the treatment of active LN in adults [134]. In a Swedish LN cohort, low baseline levels of serum BAFF were shown to be predictive of the clinical and histopathological responses to therapy, the latter based on per-protocol repeat biopsies, demonstrating a PPV of 92% for the clinical response in a subgroup of SLE patients with proliferative nephritis [135].

Among the aforementioned biomarkers, urinary MCP-1, NGAL, and CD163 deserve mention for their potential usefulness as indicators of response to therapy, as they have exhibited good predictive performances in multiple studies [35,72,79,87,101,136] (see Table 5 for the detailed metrics).

The identification of kidney tissue-based predictors of response could potentially improve the treatment selection processes and histological assessment of LN. In a retrospective analysis of Japanese patients, Ichinose et al. found that the podocyte foot process width (FPW) could be used to predict the complete renal response 6 and 12 months after the commencement of induction therapy, suggesting the use of FPW as an indicator of abnormality in LN [137].
Another study, albeit comprising a small cohort, demonstrated that glomerular C9 staining was an independent predictor of poor response to treatment 6 and 12 months after the initiation of therapy [138], lending support to the notion that a membrane attack complex (MAC)-mediated injury may be a major driver of tissue injury in LN [139].

Metrics of biomarkers of responses to therapy in LN, as derived from the present review, are summarised in Table 5.

### Table 5. Performances of selected biomarkers of responses to therapy in LN.

| Biomarker | Sample | Main Findings | References |
|-----------|--------|---------------|------------|
| **Autoantibodies** | | | |
| Anti-dsDNA (-) (disappearance at month 6) | Serum/Plasma | Sens.: 70%; spec.: 56%; PPV: 67%; NPV: 59% to predict a CRR by month 12 | Mejia-Vilet et al., 2020 [101] |
| **Complement** | | | |
| C3 (↑) (normalization or 25% increase at month 6) | Serum/Plasma | Sens.: 65–70%; spec.: 67–72%; PPV: 73–75%; NPV: 62–63% to predict CRR by month 12 | Mejia-Vilet et al., 2020 [101] |
| **Kidney disease-related markers** | | | |
| Proteinuria (↓) (baseline levels 0.1–0.87 g/24 h) | Urine | Low levels are predictive of CRR at 6 months (OR = 4.3) after immunosuppressive therapy | Ichinose et al., 2018 [137] |
| uPCR (↓) (<1.5 g/g at month 6) | Urine | Sens.: 86%; spec.: 81%; PPV: 81%; NPV: 86% to predict CRR by month 12 | Mejia-Vilet et al., 2020 [101] |
| **Cytokines/chemokines** | | | |
| APRIL (↑) (baseline levels >4 ng/mL) | Serum/Plasma | Predictive of treatment failure after six months: AUC = 0.71; sens.: 65%; spec.: 87%; PPV: 93%; NPV: 54% | Treamtrakpanon et al., 2012 [140] |
| BAFF (↓) (baseline levels <1.5 ng/mL) | Serum/Plasma | Predictive of clinical (PPV: 87%) and histopathological response (PPV: 83%) (mean follow up: 8.1 months) | Parodis et al., 2015 [135] |
| IL-8 (↓) (baseline levels) | Serum/Plasma | Lower values predictive of treatment response after 1-year: AUC = 0.64 | Wolf et al., 2016 [141] |
| IL-23 (↓) (baseline levels) | Serum/Plasma | Predictor for outcome of therapy of induction of remission of active LN: AUC = 0.87 | Dedong et al., 2019 [77] |
| MCP-1 (↑) (baseline levels) | Urine | Predictive of response to treatment with rituximab at 6 (ORadj = 2.6) and 12 months (ORadj = 0.6) | Davies et al., 2021 [72] |
| **Other proteins** | | | |
| Axl (↑) (baseline levels ≥36.6 ng/mL) | Serum/Plasma | Predictive of histological response: OR = 5.5; ORadj = 9.3. Decreased levels in responders compared with non-responders after induction therapy. | Parodis et al., 2019 [131] |
| CD163 (↓) (<370 ng/mmol at month 6) | Urine | Sens.: 90%; spec.: 87%; PPV: 87%; NPV: 90% to predict a CRR by month 12. | Mejia-Vilet et al., 2020 [101] |
| CSF-1 (↓) (decrease ≥25% after initiation of therapy) | Serum/Plasma | Predictive of response to therapy and remission: PPV: 88%; NPV: 58% | Menke et al., 2015 [125] |
| HNP1-3 (↓) (baseline levels) | Serum/Plasma | Predictive of proteinuria remission (mean follow up of 5.5 years): multivariate hazard = 0.2 | Cheng et al., 2015 [142] |
| IL-2Rx (↓) (baseline levels) | Serum/Plasma | Low levels are predictive of treatment response after 1-year: AUC = 0.63 | Wolf et al., 2016 [141] |
| Biomarker | Sample | Main Findings | References |
|-----------|--------|---------------|------------|
| NGAL (↓)  | Urine  | Predictive of renal response after 6-month induction therapy: AUC = 0.78; sens.: 81%; spec.: 83%; PPV: 56%; NPV: 95% | Liu et al., 2020 [87] |
|           |        | Discrimination between complete/partial response and non-response after 6-month of induction therapy: AUC = 0.77; sens.: 73%; spec.: 68% | Satirapoj et al., 2017 [35] |
| NRP-1 (↑) | Urine  | High baseline levels are predictive of clinical response; AUC = 0.84; sens.: 87%; spec.: 72%; PPV: 88%; NPV: 71% | Torres-Salido et al., 2019 [143] |
| OPG (↓)   | Serum/Plasma | Low levels are predictive of treatment response after 1-year: AUC = 0.67 | Wolf et al., 2016 [141] |
| RBP4 (↓)  | Urine  | Low levels are predictive of proteinuria remission within 12 months of immunosuppressive therapy in active LN patients: AUC = 0.81; sens.: 82%; spec.: 89% | Go et al., 2018 [118] |
| sTNFRII (↑)| Serum/Plasma | Predictive of clinical (AUC = 0.86; sens.: 86%; spec.: 80%) and histological response (AUC = 0.90; sens.: 83%; spec.: 80%) among patients with membranous LN (mean follow up: 7.7 months) | Parodis et al., 2017 [83] |
| S100A8/A9 (↑) | Serum/Plasma | Differences in disease activity (no response vs. “showing improvement”) in response after 6 months of rituximab: ORadj = 0.3 for both | Davies et al., 2020 [144] |
| S100A12 (↑) | Serum/Plasma | Differences in disease activity (no response vs. “showing improvement”) in response after 6 months of rituximab: ORadj = 0.3 for both | Davies et al., 2020 [144] |
| TF (↑)    | Urine  | Predictive of response to treatment with rituximab at 12 months (OR = 2.4) | Davies et al., 2021 [72] |
| IgM (↑)   | Serum/Plasma | High levels are predictive of CRR at 12 months (OR = 2.1) after immunosuppressive therapy | Ichinose et al., 2018 [137] |
| Lymphocyte count (↑) | Serum/Plasma | High levels are predictive of CRR at 12 months (OR = 2.4) after immunosuppressive therapy | Ichinose et al., 2018 [137] |

**MicroRNAs**

| MicroRNA | Sample | Effect | Reference |
|-----------|--------|--------|-----------|
| miRNA-31-5p (↑) | Urine | Significantly upregulated in responder group compared to non-responders: flare time: AUC = 0.68; 12 months after treatment: AUC = 0.76 | Garcia-Vives et al., 2020 [145] |
| miRNA-107 (↑) | Urine | Significantly upregulated in responder group compared to non-responders: flare time: AUC = 0.73; 12 months after treatment: AUC = 0.73 | Garcia-Vives et al., 2020 [145] |
| miRNA-135b-5p (↑) | Urine | Significantly upregulated in responder group compared to non-responders: flare time: AUC = 0.78; sens.: 78%; spec.: 71%; 12 months after treatment: AUC = 0.86; sens.: 81%; spec.: 79% | Garcia-Vives et al., 2020 [145] |
Table 5. Cont.

| Biomarker                              | Sample               | Main Findings                                                                 | References               |
|----------------------------------------|----------------------|-------------------------------------------------------------------------------|--------------------------|
| Renal tissue markers                   |                      |                                                                               |                          |
| C9 (+) (positive staining at baseline) | Kidney biopsy        | Positive staining is predictive of poor response at 6 months: OR = 5.4; OR_adj = 4.6 | Wang et al., 2018 [138]  |
|                                        |                      |                                                                               |                          |
| Podocyte foot process width (↓)        | Kidney biopsy        | Smaller width is predictive of CRR after induction therapy at 6 months (OR = 4.9) and 12 months (OR = 5.8) after immunosuppressive therapy | Ichinose et al., 2018 [137] |

Biomarkers are structured into subgroups (highlighted in bold) based on clinical/functional affinities. Anti-dsDNA: anti-double-stranded DNA; APRIL: a proliferation-inducing ligand; AUC: area under the curve; BAFF: B-cell-activating factor belonging to the TNF ligand superfamily; CRR: complete renal response; CSF-1: colony stimulating factor 1; C3: complement component 3; C9: complement component 9; HNP1-3: human neutrophil peptide 1-3; HR: hazard ratio; IgM: immunoglobulin M; IL-2Rα: interleukin 2 receptor alpha; LN: lupus nephritis; miRNA: microRNA; MCP-1: monocyte chemoattractant protein 1; NGAL: neutrophil gelatinase associated lipocalin; NPV: negative predictive value; NRP-1: neuropilin 1; OPG: osteoprotegerin; OR: odds ratio; PPV: positive predictive value; RBP4: retinol-binding protein 4; sens.: sensitivity; spec.: specificity; sTNFRII: soluble tumour necrosis factor receptor II; TF: transferrin; uPCR: urine protein to creatinine ratio; ↑: increased; ↓: decreased; (-): negativity; (+): positivity.

3.4. Prognostic Biomarkers

Proteinuria is the current gold standard among clinical markers of LN surveillance [1], and the proteinuria levels post-treatment have been shown to be a robust predictor of long-term renal outcomes in LN in a series of recent studies [146–149]. Proteinuria has shown a satisfactory negative predictive value, yet a poorer positive predictive value in predicting renal flares (NPV: 85%) [106], and remission with regard to proteinuria (defined as a value of <0.3 g/g creatinine or dipstick test results of trace or lower in three consecutive urinary protein tests over a period of six months) was found to be an indicator of a good prognosis in patients with diffuse proliferative LN in a Korean cohort (risk ratio (RR) of a composite outcome of mortality and development of end-stage kidney disease (ESKD): 0.2; \( p < 0.05 \)) [150]. This is in conformity with the aforementioned report series, where the proteinuria levels <0.7 to 0.8 g/day were found to be appropriate predictors of a favourable prognosis over a longer term in patients with LN [146–148].

Among the traditional immunological biomarkers, low levels of C3 have been shown to be a risk factor for renal failure within 20 years (RR_adj = 2.0; \( p = 0.01 \)) in a large cohort of SLE patients [4].

In a previous cohort study, high baseline levels of urinary VCAM-1 and ALCAM were predictive of renal function deterioration defined as a decline in eGFR by \( \geq 25\% \) at the 10-year follow-up, yielding a sensitivity of 91% and 73% and a specificity of 76% and 72%, respectively [99].

Anti-neutrophil cytoplasmic antibodies (ANCAs) comprise a family of antibodies directed against cytoplasmic antigens of neutrophils and are a key feature of specific forms of small-vessel vasculitides. Some of the ANCAs have been shown to be strongly associated with so-called “pauci-immune” glomerulonephritides due to the absence of deposits of immune complexes within the glomerular tuft [151,152]. In two retrospective studies of Chinese patients with LN, Wang et al. explored the clinical relevance of ANCAs in LN [153,154]. In these works, anti-myeloperoxidase (MPO) ANCA was demonstrated to be the most prevalent ANCA in ANCA-positive LN patients. An increased risk of mortality in ANCA-positive LN patients compared with ANCA-negative LN patients was observed both in the first (HR_adj = 3.4; \( p = 0.03 \)) and the second study (RR_adj = 3.6; \( p = 0.016 \)).

Novel kidney tissue-based biomarkers may prove to be promising prognostic tools, complementary to the traditional features assessed for the histopathological classification and characterisation of LN. Despite being rather neglected in the current classification schemes, tubulointerstitial lesions are well-known negative prognostic indicators [155–158] and have now been suggested for incorporation into the quantitative scoring system of the revised...
International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2016 classification [159,160]. Vascular lesions have also been shown to have a possible role as predictors of unfavourable renal outcomes in LN [96,161–163], but a standardised approach and terminology in the evaluation of vasculopathy in SLE and LN are currently lacking [159]. In a retrospective analysis of 202 biopsy-proven LN patients, Leatherwood et al. demonstrated that interstitial fibrosis and tubular atrophy were strong predictors of ESKD (HR_{adj} = 5.2; 95% confidence interval (CI): 2.5–10.6) and death (HR_{adj} = 4.2; 95% CI: 1.3–13.9) at a follow-up of up to 25 years [164]. In the same study, vascular injury was also found to be associated with ESKD (HR_{adj} = 2.1; 95% CI: 1.2–3.8), although a statistical significance was not reached after adjustment for the serum creatinine and ISN/RPS class [164].

Recently, two studies investigated how different pathways of complement activation may play a role in predicting long-term outcomes in LN [165,166]. Ding et al. showed that arteriolar C4d deposition and C4d and C3c co-deposition were independent risk factors for a poor renal prognosis, defined as ESKD or doubling of the serum creatinine (HR_{adj} = 2.3 and HR_{adj} = 3.7, respectively; p < 0.05 for both) [165]. Moreover, the authors of these works observed an association between arteriolar C4d deposition and renal microvascular lesions, which strengthens the notion of a role as a complement in LN pathogenesis [167,168]. Additionally, Kim et al. found that glomerular C3 deposition without C1q and C4 was predictive of kidney disease progression, arguing for key roles in the alternative complement pathway in LN pathogenesis [166].

A summary of the biomarkers of long-term outcomes in LN is detailed in Table 6.

**Table 6. Performances of selected prognostic biomarkers in LN.**

| Biomarker            | Sample   | Main Findings                                                                 | References                        |
|----------------------|----------|-------------------------------------------------------------------------------|-----------------------------------|
| **Autoantibodies**   |          |                                                                               |                                   |
| ANCAs (+)            | Serum/Plasma | Predictive of increased mortality: RR_{adj} = 3.6; HR = 3.3; HR_{adj} = 3.4 | Wang et al., 2016 [153]; Wang et al., 2020 [154] |
| Anti-C1q * (+)       | Serum/Plasma | Risk factor for composite outcome (death and doubling of serum creatinine or ESKD) after median follow up of 42 months: HR = 3.9; HR_{adj} = 1.2 | Pang et al., 2016 [52] |
| **Complement**       |          |                                                                               |                                   |
| C3 (low)             | Serum/Plasma | Predictive of renal failure within 20 years: RR_{adj} = 2.0                  | Petri et al., 2021 [4] |
| **Kidney disease-related markers** |          |                                                                               |                                   |
| Creatinine (↑)       | Serum/Plasma | Higher baseline levels predictive of ESKD: HR = 2.1                          | Chen et al., 2019 [169] |
|                      |           | Risk factor for composite outcome after median follow up of 42 months:       | Pang et al., 2016 [52] |
|                      |           | RR_{adj} = 4.7                                                               |                                   |
| Proteinuria (↑)      | Urine     | Predictive of renal failure within 20 years: RR_{adj} = 2.8                  | Petri et al., 2021 [4] |
| (>500 mg/24 h)       |           | Proteinuric remission indicates good prognosis in patients with diffuse proliferative LN (mean follow up: 157.9 months). RR of composite outcome (sum of mortality and incidence of end stage renal disease) = 0.2 | Koo et al., 2016 [150] |
| Biomarker | Sample | Main Findings | References |
|-----------|--------|---------------|------------|
| **Cell adhesion molecules** | | | |
| ALCAM(†) (ALCAM/Cr > 0.18 × 10^-4) | Urine | High baseline values are predictive of renal function deterioration (decline in eGFR by ≥ 25%) at the 10-year follow up. AUC = 0.74; sens.: 73%; spec.: 72%; OR = 6.1 | Parodis et al., 2020 [99] |
| VCAM-1 (†) (VCAM1/Cr > 0.32 × 10^-4) | Urine | High baseline values are predictive of renal function deterioration (decline in eGFR by ≥ 25%) at the 10-year follow up. AUC = 0.77; sens.: 91%; spec.: 76%; OR= 22.9 | Parodis et al., 2020 [99] |
| Other proteins/soluble molecules | | | |
| Axl (†) (>46.1 ng/mL) | Serum/Plasma | High post treatment values predict good renal outcome (creatinine ≤ 88.4 µmol/L) over 10 years. AUC = 0.71; sens.: 42%; spec.: 91%; PPV: 80%; NPV: 65% | Parodis et al., 2019 [131] |
| CD163 (†) (>370 ng/mmol) | Urine | Increased risk for doubling of serum creatinine within 6 (HR = 2.8) and 12 (HR = 3.6) months | Mejia-Vilet et al., 2020 [101] |
| EGF (↓) (EGF/Cr < 5.3 ng/mg at flare time) | Urine | Predicts doubling serum creatinine within 2 years. AUC = 0.82; sens.: 81%; spec.: 77% | Mejia-Vilet et al., 2021 [170] |
| sTNFRII (†) (>7.1 ng/mL) | Serum/Plasma | Higher post treatment levels in CKD ≥ 3 patients compared to CKD1-2 patients. AUC = 0.73; sens.: 73%; spec.: 75% | Parodis et al., 2017 [83] |
| **Renal tissue markers** | | | |
| Arteriolar C4d deposition (+) | Kidney biopsy | Risk factor for poor renal outcome (average follow up time: 55.8 months): HR = 2.1 | Ding et al., 2021 [165] |
| Cellular crescents (+) | Kidney biopsy | Predictive of ESKD: HR = 4.4 (cellular crescents) and HR = 5.9 (fibrous crescents) | Chen et al., 2019 [169] |
| Fibrous crescents (+) | Kidney biopsy | | |
| Glomerular C3 deposition (+) | Kidney biopsy | Positive staining without C1q and C4 deposition (suggestive of alternative pathway-limited activation) is associated with progression of kidney disease (≥ 50% reduction in eGFR from baseline values or advancement to ESKD) after a mean follow-up of 5.4 years: HR = 4.8; HRadj = 3.5 | Kim et al., 2020 [166] |
| IFTA (+) (≥ 25% of the surface cortical area) | Kidney biopsy | Moderate/severe IFTA is associated with ESKD (HRadj = 5.2) and death (HRadj = 4.2) | Leatherwood et al., 2019 [164] |
| Mannose enriched N-glycan expression (GNA reactivity ≥ 50%) | Kidney biopsy | Increased risk of developing CKD after 1 year: AUC = 0.83; sens.: 67%; spec.: 94%; PPV: 80%; NPV: 87%; OR = 24.3 | Alves et al., 2021 [75] |
| Vascular injury (+) (≥ 25% subintimal narrowing of the lumen) | Kidney biopsy | Moderate/severe vascular injury is associated with ESKD (HRadj = 2.1) | Leatherwood et al., 2019 [164] |

Biomarkers are structured into subgroups (highlighted in bold) based on clinical/functional affinities. ALCAM: activated leukocyte cell adhesion molecule; ANCA: anti-neutrophil cytoplasmic antibody; AUC: area under the curve; CKD: chronic kidney disease; Cr: creatinine; C1q: complement component 1q; C3: complement component 3; C4: complement component 4; C4d: complement component 4d; EGF: epidermal growth factor; eGFR: estimated glomerular filtration rate; ESKD: end stage kidney disease; GNA: galantus nivalis agglutinin reaction; HR: hazard ratio; IFTA: interstitial fibrosis and tubular atrophy; NPV: negative predictive value; OR: odds ratio; PPV: positive predictive value; RR: risk ratio; sens.: sensitivity; spec.: specificity; sTNFRII: soluble tumor necrosis factor alpha receptor II; VCAM-1: vascular cell adhesion molecule 1; (+): positivity; †: increased; ↓: decreased. * Antibodies against the epitope A08 of C1q.
4. Conclusions and Perspectives

The relevance of renal involvement in the global disease burden of SLE is reflected by the extensive research on drug development and novel biomarkers toward the improvement of clinical practice and optimisation of disease outcomes. Several new molecules have been investigated for their prospect as potential diagnostic, monitory, or prognostic biomarkers in LN over the last decade, with encouraging results for several of them. Among these, urinary MCP-1 and NGAL showed an adequate diagnostic ability, as well as the ability to reflect disease activity and predict response to therapy. Moreover, our search suggests that urinary VCAM-1, CD163, and ALCAM may hold promise as versatile biomarkers for LN, with potential implications for diagnostic, monitoring, and prognostic purposes, as their biomarker potential has been repeatedly validated across multiple independent cohorts and laboratories.

Given the complexity and the heterogeneity of LN, it is unlikely that one single biomarker is sufficient to capture its entire spectrum of features. Several studies highlighted the necessity of combining different molecules to improve disease evaluations [18,72,87,107]. The direction we foreshadow is the development of panels that integrate different biomarkers for different purposes, thus achieving the best possible accuracy and precision.

While a kidney biopsy remains the gold standard for the diagnosis and classification of LN [6], only a minority of studies investigated kidney tissue-based biomarkers. Research seems to lean toward fluid-based biomarkers, aiming to implement LN management through less invasive modes. In alignment with this aim, urine constitutes an attractive source for sampling, since it is easily obtainable, non-invasive, and theoretically more specific of kidney involvement than peripheral blood. However, it is important to underline the importance of the integration of tissue-based information in fluid-based biomarker research as a strategy to accurately determine the best peripheral molecular readouts for kidney-specific injury [171,172]. In this regard, studies for the identification of biomarkers that could be integrated into the current histopathological classification [159] for a more granular diagnostic and prognostic stratification of LN patients are needed and form an integral part of the future research agenda in this field.

Among the limitations of this systematic literature review, some aspects need to be underlined as possible sources of bias. Firstly, although not unexpectedly, the biomarker studies deemed eligible for data extraction were characterised by a high degree of heterogeneity in terms of design, patient populations, and definitions of outcomes, which, together with the inevitable inconsistency of laboratory testing across studies, introduces limitations into the generalisability of the findings and makes conclusions hard to draw. For instance, different approaches were followed for the determination of the cut-off values across studies investigating the same molecules, and the diagnosis of LN was not confirmed by a histological assessment with a kidney biopsy in all the studies. Secondly, descriptions of participant characteristics were not sufficiently explicit in all studies. Thirdly, important confounding factors were not always adequately accounted for in the investigations. Detailed information about such limiting factors is presented in Supplementary Tables S2–S4. The overall lack of validation studies in independent cohorts is a major limitation in biomarker research. Efforts should be made to prompt more concerted investigations following centralised approaches. In such efforts, the Lupus Nephritis Trials Network (http://lupusnephritis.org, accessed on 8 August 2022) and other similar initiatives could be instrumental.

Nevertheless, in view of the rapid technological advancements, we foresee a revolution toward the optimised and personalised management of patients with LN in the years to come using a battery of next-generation biomarkers.
Supplementary Materials: The following supporting information can be downloaded at https://www.mdpi.com/article/10.3390/jcm11195759/s1: Figure S1: PRISMA flow diagram for systematic reviews that included searches of databases and registers only. Table S1. Search in Medline. Table S2. Risk of bias assessment of cross-sectional studies. Table S3. Risk of bias assessment of meta-analyses. Table S4. Risk of bias assessment of cohort studies. Table S5. Ethnicity and/or nationality of the populations in the included studies.

Author Contributions: Conceptualisation, L.P., J.L., C.M. and I.P.; methodology, L.P., J.L., C.M. and I.P.; investigation, L.P. and J.L.; writing—original draft preparation, L.P., J.L., C.M. and I.P.; writing—review and editing, J.L., C.M. and I.P.; supervision, I.P.; and funding acquisition, C.M. and I.P. All authors have read and agreed to the published version of the manuscript.

Funding: C.M. research is supported by NIH R01 AR074096 and the Lupus Research Alliance. I.P. has received grants from the Swedish Rheumatism Association (R-941095), King Gustaf V’s 80-year Foundation (FAI-2020-0741), Professor Nanna Svartz Foundation (2020-00368), Ulla and Roland Gustafsson Foundation (2021–26), Region Stockholm (FoUI-955483), and Karolinska Institutet. This publication has also been supported with funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant number 831434 for the 3TR project; JU received support from the EU Horizon 2020 research and innovation programme and EFPIA.

Institutional Review Board Statement: Not applicable.

Data Availability Statement: No new data were created or analyzed in this study. Data sharing is not applicable to this article.

Acknowledgments: We thank the librarians Love Strandberg and Narcisa Hannerz from the Karolinska Institutet library (KIB) for their assistance with the construction of the search strategy.

Conflicts of Interest: L.P., J.L. and C.M. declare that they have no conflicts of interest. I.P. received research funding and/or honoraria from Amgen, AstraZeneca, Aurinia Pharmaceuticals, Eli Lilly and Company, Gilead Sciences, GlaxoSmithKline, Janssen Pharmaceuticals, Novartis, Otsuka Pharmaceutical, and F. Hoffmann-La Roche AG.

References
1. Anders, H.-J.; Saxena, R.; Zhao, M.-H.; Parodis, I.; Salmon, J.E.; Mohan, C. Lupus nephritis. Nat. Rev. Dis. Prim. 2020, 6, 1–25. [CrossRef] [PubMed]
2. Almaani, S.; Meara, A.; Rovin, B.H. Update on Lupus Nephritis. Clin. J. Am. Soc. Nephrol. 2017, 12, 825–835. [CrossRef] [PubMed]
3. Tektonidou, M.; Dasgupta, A.; Ward, M.M. Risk of End-Stage Renal Disease in Patients With Lupus Nephritis, 1971-2015: A Systematic Review and Bayesian Meta-Analysis. Arthritis Rheumatol. 2016, 68, 1432–1441. [CrossRef] [PubMed]
4. Califf, R.M. Biomarker definitions and their applications. Exp. Biol. Med. 2018, 243, 213–221. [CrossRef]
5. F. Hoffmann-La Roche AG.

Author Contributions: Conceptualisation, L.P.; methodology, L.P.; investigation, L.P.; writing—original draft preparation, L.P.; writing—review and editing, L.P.; supervision, L.P.; and funding acquisition, L.P. All authors have read and agreed to the published version of the manuscript.

Funding: C.M. research is supported by NIH R01 AR074096 and the Lupus Research Alliance. I.P. has received grants from the Swedish Rheumatism Association (R-941095), King Gustaf V’s 80-year Foundation (FAI-2020-0741), Professor Nanna Svartz Foundation (2020-00368), Ulla and Roland Gustafsson Foundation (2021–26), Region Stockholm (FoUI-955483), and Karolinska Institutet. This publication has also been supported with funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant number 831434 for the 3TR project; JU received support from the EU Horizon 2020 research and innovation programme and EFPIA.

Institutional Review Board Statement: Not applicable.

Data Availability Statement: No new data were created or analyzed in this study. Data sharing is not applicable to this article.

Acknowledgments: We thank the librarians Love Strandberg and Narcisa Hannerz from the Karolinska Institutet library (KIB) for their assistance with the construction of the search strategy.

Conflicts of Interest: L.P., J.L. and C.M. declare that they have no conflicts of interest. I.P. received research funding and/or honoraria from Amgen, AstraZeneca, Aurinia Pharmaceuticals, Eli Lilly and Company, Gilead Sciences, GlaxoSmithKline, Janssen Pharmaceuticals, Novartis, Otsuka Pharmaceutical, and F. Hoffmann-La Roche AG.

References
1. Anders, H.-J.; Saxena, R.; Zhao, M.-H.; Parodis, I.; Salmon, J.E.; Mohan, C. Lupus nephritis. Nat. Rev. Dis. Prim. 2020, 6, 1–25. [CrossRef] [PubMed]
2. Califf, R.M. Biomarker definitions and their applications. Exp. Biol. Med. 2018, 243, 213–221. [CrossRef]
3. F. Hoffmann-La Roche AG.
14. Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021, 372, n71. [CrossRef] [PubMed]

15. Joanna Briggs Institute. Checklist forit Case Control AppraStudisal Tooles. Available online: https://jbi.global/critical-appraisal-tools (accessed on 4 July 2022).

16. Bagavant, H.; Fu, S.M. Pathogenesis of kidney disease in systemic lupus erythematosus. Curr. Opin. Rheumatol. 2009, 21, 489–494. [CrossRef] [PubMed]

17. Bonanni, A.; Vaglio, A.; Bruschi, M.; Sinico, R.A.; Cavagna, L.; Moroni, G.; Franceschini, F.; Allegri, L.; Pratesi, F.; Migliorini, P.; et al. Multi-antibody composition in lupus nephritis: Isotype and antigen specificity make the difference. Autoimmun. Rev. 2015, 14, 692–702. [CrossRef]

18. Huang, Y.; Chen, L.; Chen, K.; Huang, F.; Feng, Y.; Xu, Z.; Wang, W. Anti–α-enolase antibody combined with β2 microglobulin evaluated the incidence of nephritis in systemic lupus erythematosus patients. Lupus 2019, 28, 365–370. [CrossRef]

19. Bruschi, M.; Sinico, R.A.; Moroni, G.; Pratesi, F.; Migliorini, P.; Galetti, M.; Murtas, C.; Tincani, A.; Madaio, M.; Radice, A.; et al. Glomerular autoimmune multicomponents of human lupus nephritis in vivo: Alpha-enolase and annexin Al. J. Am. Soc. Nephrol. JASN 2014, 25, 2483–2498. [CrossRef]

20. Bruschi, M.; Moroni, G.; Sinico, R.A.; Franceschini, F.; Fredi, M.; Vaglio, A.; Cavagna, L.; Petretto, A.; Pratesi, F.; Migliorini, P.; et al. Serum IgG2 antibody multicomposition in systemic lupus erythematosus and lupus nephritis (Part 1): Cross-sectional analysis. Rheumatology 2020, 60, 3176–3188. [CrossRef] [PubMed]

21. Bruschi, M.; Moroni, G.; Sinico, R.A.; Franceschini, F.; Fredi, M.; Vaglio, A.; Cavagna, L.; Petretto, A.; Pratesi, F.; Migliorini, P.; et al. Serum IgG2 antibody multicomposition in systemic lupus erythematosus and lupus nephritis (Part 2): Prospective study. Rheumatology 2020, 60, 3388–3397. [CrossRef] [PubMed]

22. Calich, A.L.; Borba, E.F.; Ugolini-Lopes, M.R.; da Rocha, L.F.; Bonfá, E.; Fuller, R. Serum uric acid levels are associated with lupus nephritis in patients with normal renal function. Clin. Rheumatol. 2018, 37, 1223–1228. [CrossRef] [PubMed]

23. Yang, Z.; Zhang, Z.; Qin, B.; Wu, P.; Zhong, R.; Zhou, L.; Liang, Y. Human Epididymis Protein 4: A Novel Biomarker for Lupus Nephritis and Chronic Kidney Disease in Systemic Lupus Erythematosus. J. Clin. Lab. Anal. 2016, 30, 897–904. [CrossRef]

24. Hafez, E.A.; Hassan, S.A.E.-M.; Teama, M.A.M.; Badr, F.M. Serum uric acid as a predictor for nephritis in Egyptian patients with systemic lupus erythematosus. Lupus 2020, 30, 378–384. [CrossRef] [PubMed]

25. Winkles, J.A. The TWEAK–Fn14 cytokine–receptor axis: Discovery, biology and therapeutic targeting. Nat. Rev. Drug Discov. 2008, 7, 411–425. [CrossRef]

26. Salem, M.N.; Taha, H.A.; Abd El-Fattah El-Feqi, M.; Eesa, N.N.; Mohamed, R.A. Urinary TNF-like weak inducer of apoptosis (TWEAK) as a biomarker of lupus nephritis. Z Rheumatol. 2018, 77, 71–77. [CrossRef] [PubMed]

27. Reyes-Martinez, F.; Perez-Navarro, M.; Rodriguez-Matias, A.; Soto-Abraham, V.; Gutierrez-Reyes, G.; Medina-Avila, Z.; Valdez-Ortiz, R. Assessment of urinary TWEAK levels in Mexican patients with untreated lupus nephritis: An exploratory study. Nefrologia 2018, 38, 152–160. [CrossRef]

28. Michaelson, J.S.; Wisniacki, N.; Burkly, L.C.; Puttermann, C. Role of TWEAK in lupus nephritis: A bench-to-bedside review. J. Autoimmun. 2012, 39, 130–142. [CrossRef]

29. Xia, Y.; Herlitz, L.C.; Gindea, S.; Wen, J.; Pawar, R.D.; Misharin, A.; Pearlman, H.; Wu, L.; Wu, P.; Michaelson, J.S.; et al. Deficiency of Fibroblast Growth Factor-Inducible 14 (Fn14) Preserves the Filtration Barrier and Ameliorates Lupus Nephritis. J. Am. Soc. Nephrol. 2014, 26, 1053–1070. [CrossRef]

30. Elsaid, D.S.; Abdel Noor, R.A.; Shalaby, K.A.; Haroun, R.A.-H. Urinary Tumor Necrosis Factor-Like Weak Inducer of Apoptosis (uTWEAK) and Urinary Monocyte Chemo-attractant Protein-1 (uMCP-1): Promising Biomarkers of Lupus Nephritis Activity? Saudi J. Kidney Dis. Transplant. Off. Publ. Saudi Cent. Organ Transplant. Saudi Arab. 2021, 32, 19–29. [CrossRef]

31. Miroioglu, S.; Cinar, S.; Yazici, H.; Ozuik, Y.; Kilicaslan, I.; Gul, A.; Ocal, L.; Inanc, M.; Artim-Esen, B. Serum and urine TNF-like weak inducer of apoptosis, monocyte chemoattractant protein-1 and neutrophil gelatinase-associated lipocalin as biomarkers of disease activity in patients with systemic lupus erythematosus. Lupus 2020, 29, 379–388. [CrossRef]

32. Choe, J.-Y.; Kim, S.-K. Serum TWEAK as a biomarker for disease activity of systemic lupus erythematosus. Inflamm Res. 2016, 65, 479–488. [CrossRef] [PubMed]

33. Chakraborty, S.; Kaur, S.; Gupta, S.; Batra, S.K. The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer. Biochim. Biophys. Acta BBA Rev. Cancer 2012, 1826, 129–169. [CrossRef] [PubMed]

34. Rubinstein, T.; Pitashny, M.; Puttermann, C. The novel role of neutrophil gelatinase-B associated lipocalin (NGAL)/Lipocalin-2 as a biomarker for lupus nephritis. Autoimmun. Rev. 2008, 7, 229–234. [CrossRef]

35. Satirapoj, B.; Kittiyakara, C.; Leelavahanichkul, A.; Avihingsanon, Y.; Supasyndh, O. Urine neutrophil gelatinase-associated lipocalin to predict renal response after induction therapy in active lupus nephritis. BMC Nephrol. 2017, 18, 263. [CrossRef]

36. Fang, Y.G.; Chen, N.N.; Cheng, Y.B.; Sun, S.J.; Li, H.X.; Sun, F.; Xiang, Y. Urinary neutrophil gelatinase-associated lipocalin for diagnosis and estimating activity in lupus nephritis: A meta-analysis. Lupus 2015, 24, 1529–1539. [CrossRef] [PubMed]

37. Brunner, H.I.; Bennett, M.R.; Mina, R.; Suzuki, M.; Petri, M.; Kiani, A.N.; Pendl, J.; Witte, D.; Ying, J.; Rovin, B.H.; et al. Association of noninvasively measured renal protein biomarkers with histologic features of lupus nephritis. Arthritis Care Res. 2012, 64, 2687–2697. [CrossRef]
38. Torres-Salido, M.T.; Cortes-Hernandez, J.; Vidal, X.; Pedrosa, A.; Vilardell-Tarres, M.; Ordí-Ros, J. Neutrophil gelatinase-associated lipocalin as a biomarker for lupus nephritis. *Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. Eur. Ren. Assoc.* 2014, 29, 1740–1749. [CrossRef]

39. El Shahawy, M.S.; Hemida, M.H.; Abdel-Hafez, H.A.; El-Baz, T.Z.; Lotfy, A.-W.M.; Emran, T.M. Urinary neutrophil gelatinase-associated lipocalin as a marker for disease activity in lupus nephritis. *Scand. J. Clin. Lab. Investig.* 2018, 78, 264–268. [CrossRef]

40. Gao, Y.; Wang, B.; Cao, J.; Feng, S.; Liu, B. Elevated Urinary Neutrophil Gelatinase-Associated Lipocalin Is a Biomarker for Lupus Nephritis: A Systematic Review and Meta-Analysis. *BioMed Res. Int.* 2020, 2020, 2768326. [CrossRef]

41. A Gómez-Puerta, J.; Ortiz-Reyes, B.; Urrego, T.; Vanegas-García, A.L.; Muñoz, C.H.; A González, L.; Cervera, R.; Vásquez, G. Urinary neutrophil gelatinase-associated lipocalin and monocye chemoattractant protein 1 as biomarkers for lupus nephritis in Colombian SLE patients. *Lupus* 2017, 25, 657–664. [CrossRef]

42. Wang, G.; Tam, L.-S.; Kwan, B.C.-H.; Li, E.K.-M.; Chow, K.-M.; Luk, C.C.-W.; Li, P.K.-T.; Szeto, C.-C. Expression of miR-146a and miR-155 in the urinary sediment of systemic lupus erythematosus. *Clin. Rheumatol.* 2011, 31, 435–440. [CrossRef]

43. Khoshmirsafa, M.; Kianmehr, N.; Falak, R.; Mowlah, S.J.; Seif, F.; Mirzaei, B.; Valizadeh, M.; Shekarabi, M. Elevated expression of miR-21 and miR-155 in peripheral blood mononuclear cells as potential biomarkers for lupus nephritis. *Int. J. Rheum. Dis.* 2018, 22, 458–467. [CrossRef] [PubMed]

44. Nakhjavani, M.; Etemadi, J.; Pourlak, T.; Mirhosaini, Z.; Vahed, S.Z.; Abediazar, S. Plasma levels of miR-181a and miR-223 expression with the potential value of biomarkers for the diagnosis of systemic lupus erythematosus and predicting lupus nephritis. *J. Gene Med.* 2019, 23, e3326. [CrossRef]

45. Barbano, C.; A Gómez-Puerta, J.; Muñoz-Vahos, C.; Vanegas-García, A.; Rojas, M.; Vásquez, G.; Castaño, D. HMGB1 + microparticles present in urine are biomarkers in patients with systemic lupus erythematosus. *Eur. J. Immunol.* 2018, 49, 323–335. [CrossRef]

46. Yoshimoto, S.; Nakatani, K.; Iwano, M.; Asai, O.; Samejima, K.-I.; Sakai, H.; Terada, M.; Harada, K.; Akai, Y.; Shiuki, H.; et al. Elevated Levels of Fractalkine Expression and Accumulation of CD16+ Macrophages in Glomeruli of Active Lupus Nephritis. *Am. J. Kidney Dis.* 2007, 50, 47–58. [CrossRef] [PubMed]

47. Abdul-Maksoud, R.S.; Rashad, N.M.; Elsayed, W.S.H.; Ali, M.A.; Kamal, N.M.; Zidan, H.E. Circulating miR-181a and miR-223 expression as biomarkers of disease activity in systemic lupus erythematosus and predicting lupus nephritis. *J. Gene Med.* 2020, 22, 458–467. [CrossRef] [PubMed]

48. Liu, X.-R.; Qi, Y.-Y.; Zhao, Y.-F.; Cui, Y.; Wang, X.-Y.; Zhao, Z.-Z. Albumin-to-globulin ratio (AGR) as a potential marker of predicting lupus nephritis in Chinese patients with systemic lupus erythematosus. *Lupus* 2021, 30, 412–420. [CrossRef] [PubMed]

49. Kwon, O.C.; Lee, E.-J.; Oh, J.S.; Hong, S.; Lee, C.-K.; Yoo, B.; Park, M.-C.; Kim, Y.-G. Plasma immunoglobulin binding protein 1 as a predictor of development of lupus nephritis. *Lupus* 2020, 29, 547–553. [CrossRef]

50. Mok, C.C.; Ding, H.H.; Khambouli, M.; Mohan, C. Axl, Ferritin, Insulin-Like Growth Factor Binding Protein 2, and Tumor Necrosis Factor Receptor Type II as Biomarkers in Systemic Lupus Erythematosus. *Arthr. Care Res.* 2016, 68, 1303–1309. [CrossRef]

51. Barnado, A.; Carroll, R.; Casey, C.; Wheless, L.; Denny, J.; Crofford, L. Phenome-wide association study identifies dsDNA as a driver of major organ involvement in systemic lupus erythematosus. *Lupus* 2018, 28, 66–76. [CrossRef]

52. Tang, C.; Fang, M.; Tan, G.; Zhang, S.; Yang, B.; Li, Y.; Zhang, T.; Saxena, R.; Mohan, C.; Wu, T. Discovery of Novel Circulating Immune Complexes in Lupus Nephritis Using Immunoepitomics. *Front. Immunol.* 2022, 13, 850015. [CrossRef]

53. Ishizaki, J.; Saito, K.; Nawata, M.; Mizuno, Y.; Tokunaga, M.; Sawamukai, N.; Tamura, M.; Hirata, S.; Yamaoka, K.; Hasegawa, H.; et al. Low complements and high titre of anti-Sm antibody as predictors of histopathologically proven silent lupus nephritis without abnormal urinalysis in patients with systemic lupus erythematosus. *Rheumatology* 2014, 54, 405–412. [CrossRef]

54. Martin, M.; Trattner, R.; Nilsson, S.C.; Björk, A.; Zickert, A.; Blom, A.M.; Gunnarsson, I. Plasma C4d Correlates With C4d Deposition in Kidneys and With Treatment Response in Lupus Nephritis Patients. *Front. Immunol.* 2020, 11, 582737. [CrossRef]

55. Phatak, S.; Chaurasia, S.; Mishra, S.K.; Gupta, R.; Agrawal, V.; Aggarwal, A.; Misra, R. Urinary B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL): Potential biomarkers of active lupus nephritis. *Clin. Exp. Immunol.* 2016, 187, 376–382. [CrossRef] [PubMed]
98. O'Reilly, M.S.; Holmgren, L.; Shing, Y.; Chen, C.; Rosenthal, R.A.; Moses, M.; Lane, W.S.; Cao, Y.; Sage, E.; Folkman, J. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma. *Cell* 1994, 79, 315–328. [CrossRef]

99. Parodis, I.; Gokaraju, S.; Zickert, A.; Vanarsa, K.; Zhang, T.; Habazi, D.; Botto, J.; Alves, C.S.; Giannopoulos, P.; Larsson, A.; et al. ALCAM and VCAM-1 as urine biomarkers of activity and long-term renal outcome in systemic lupus erythematosus. *Rheumatology* 2019, 59, 2237–2249. [CrossRef]

100. Howe, H.S.; Kong, K.O.; Thong, B.Y.; Law, W.G.; Chia, F.L.A.; Chng, H.H.; Leung, B.P.L. Urine sVCAM-1 and sICAM-1 levels are elevated in lupus nephritis patients. *Int. J. Rheum. Dis.* 2012, 15, 13–16. [CrossRef]

101. Mejia-Vilet, J.M.; Zhang, X.L.; Cruz, C.; Cano-Verduzco, M.L.; Shapiro, J.P.; Nagaraja, H.N.; Morales-Buenrostro, L.E.; Rovin, B.H. Urinary Soluble CD163: A Novel Noninvasive Biomarker of Activity for Lupus Nephritis. *J. Am. Soc. Nephrol.* 2020, 31, 1335–1347. [CrossRef]

102. Endo, N.; Tsuboi, N.; Furuhashi, K.; Shi, Y.; Du, Q.; Abe, T.; Hori, M.; Imaizumi, T.; Kim, H.; Katsuno, T.; et al. Urinary soluble CD163 level reflects glomerular inflammation in human lupus nephritis. *Nephrol. Dial. Transplant.* 2016, 31, 2023–2033. [CrossRef] [PubMed]

103. Zhang, T.; Li, H.; Vanarsa, K.; Gidley, G.; Mok, C.C.; Petri, M.; Saxena, R.; Mohan, C. Association of Urine sCD163 With Proliferative Lupus Nephritis, Fibrinoid Necrosis, Cellular Crescents and Intrarenal M2 Macrophages. *Front. Immunol.* 2020, 11, 671. [CrossRef]

104. Bock, M.; Heijnen, I.; Trendelenburg, M. Anti-C1q Antibodies as a Follow-Up Marker in SLE Patients. *PLoS ONE* 2015, 10, e0123572. [CrossRef] [PubMed]

105. Kianmehr, N.; Khoshmirsa, M.; Shekarabi, M.; Falak, R.; Haghighi, A.; Masoodian, M.; Seif, F.; Omidi, F.; Shirani, F.; Dadfar, N. High frequency of concurrent anti-C1q and anti-dsDNA but not anti-C3b antibodies in patients with Lupus Nephritis. *J. Immunass. Immunochem.* 2021, 42, 406–423. [CrossRef]

106. Fatemi, A.; Samadi, G.; Sayedbonakdar, Z.; Smiley, A. Anti-C1q antibody in patients with lupus nephritic flare: 18-month follow-up and a nested case-control study. *Rheumatol. 2015*, 26, 233–239. [CrossRef] [PubMed]

107. Fasano, S.; Pierro, L.; Borgia, A.; Coscia, M.A.; Formica, R.;ucci, L.; Riccardi, A.; Ciccia, F. Biomarker panels may be superior over single molecules in prediction of renal flares in systemic lupus erythematosus: An exploratory study. *Rheumatology* 2020, 59, 3193–3200. [CrossRef]

108. Yap, D.Y.H.; Yung, S.; Zhang, Q.; Tang, C.; Chan, T.M. Serum level of proximal renal tubular epithelial cell-binding immunoglobulin G in patients with lupus nephritis. *Lupus* 2015, 25, 46–53. [CrossRef]

109. Selvaraja, M.; Abdullah, M.; Arip, M.; Chin, V.K.; Shah, A.; Nordin, S.A. Elevated interleukin-25 and its association to Th2 cytokines in systemic lupus erythematosus with lupus nephritis. *PLoS ONE* 2019, 14, e0224707. [CrossRef]

110. Ruchakorn, N.; Ngamjanayaporn, P.; Suangtamai, T.; Kafakson, T.; Polpanumas, C.; Petpisit, V.; Pisitkun, T.; Pisitkun, P. Performance of cytokine models in predicting SLE activity. *Arthritis Res. Ther.* 2019, 21, 287. [CrossRef]

111. Buyon, J.P.; Kim, M.Y.; Guerra, M.M.; Lu, S.; Reeves, E.; Petri, M.; Laskin, C.A.; Lockshin, M.D.; Sammaritano, L.R.; Branch, D.W.; et al. Kidney Outcomes and Risk Factors for Nephritis (Flare/De Novo) in a Multiethnic Cohort of Pregnant Patients with Lupus. *Clin. J. Am. Soc. Nephrol.* 2017, 12, 940–946. [CrossRef]

112. Dolf, S.; Abdulahad, W.H.; Arends, S.; Van Dijk, M.C.; Limburg, P.C.; Kallenborg, C.G.; Bijl, M. Urinary CD8+ T-cell counts discriminate between active and inactive nephritis. *Arthritis Res. Ther.* 2013, 15, R36. [CrossRef] [PubMed]

113. Nordin, F.; Shaharir, S.S.; Wahab, A.A.; Mustafar, R.; Gafar, A.H.A.; Said, M.S.M.; Rajalingham, S.; Shah, S.A. Serum and urine interleukin-17A levels as biomarkers of disease activity in systemic lupus erythematosus. *Int. J. Rheum. Dis.* 2019, 22, 1419–1426. [CrossRef] [PubMed]

114. Wang, Y.; Tao, Y.; Liu, Y.; Zhao, Y.; Song, C.; Zhou, B.; Wang, T.; Gao, L.; Zhang, L.; Hu, H. Rapid detection of urinary soluble intercellular adhesion molecule-1 for determination of lupus nephritis activity. *Medicine* 2018, 97, e11287. [CrossRef] [PubMed]
115. Yu, K.Y.; Yung, S.; Chau, M.K.; Tang, C.S.; Yap, D.Y.; Tang, A.H.; Ying, S.K.; Lee, C.K.; Chan, T.M. Clinico-pathological associations of serum VCAM-1 and ICAM-1 levels in patients with lupus nephritis. *Lupus* 2021, 30, 1039–1050. [CrossRef]

116. Alharazy, S.M.; Kong, N.C.; Mohed, M.; Shah, S.A.; Gafur, A.H.A.; Ba‘in, A. The role of urinary neutrophil gelatinase-associated lipocalin in lupus nephritis. *Clin. Chim. Acta* 2013, 425, 163–168. [CrossRef]

117. Wu, J.; Wei, L.; Wang, W.; Zhang, X.; Chen, L.; Lin, C. Diagnostic value of progranulin in patients with lupus nephritis and its correlation with disease activity. *Rheumatol. Int.* 2016, 36, 759–767. [CrossRef]

118. Go, D.J.; Lee, J.Y.; Kang, M.J.; Lee, E.Y.; Yi, E.C.; Song, Y.W. Urinary vitamin D-binding protein, a novel biomarker for lupus nephritis, predicts the proteinuria flares. *Lupus* 2018, 27, 1600–1615. [CrossRef]

119. Aggarwal, A.; Gupta, R.; Negi, V.S.; Rajasekhar, L.; Misra, R.; Singh, P.; Chaturvedi, V.; Sinha, S. Urinary haptoglobin, alpha-1 anti-chymotrypsin and retinol binding protein identified by proteomics as potential biomarkers for lupus nephritis. *Clin. Exp. Immunol.* 2017, 188, 254–262. [CrossRef]

120. Yu, K.Y.C.; Yung, S.; Chau, M.K.M.; O’ Tang, C.S.; Yap, D.Y.H.; Tang, A.H.N.; Ying, S.K.Y.; Lee, C.K.; Chan, T.M. Serum syndecan-1, hyaluronan and thrombomodulin levels in patients with lupus nephritis. *Rheumatology* 2021, 60, 735–750. [CrossRef]

121. Kim, K.-J.; Kim, J.-Y.; Baek, I.-W.; Kim, W.-U.; Cho, C.-S. Elevated Serum Levels of Syndecan-1 Are Associated with Renal Involvement in Patients with Systemic Lupus Erythematosus. *J. Rheumatol.* 2015, 42, 202–209. [CrossRef]

122. Smith, M.A.; Henault, J.; Karmell, J.L.; Parker, M.L.; Riggs, J.M.; Sinibaldi, D.; Taylor, D.K.; Ettinger, R.; Grant, E.P.; Sanjuan, M.A.; et al. SLE Plasma Profiling Identifies Unique Signatures of Lupus Nephritis and Discoid Lupus. *Sci. Rep.* 2019, 9, 14433. [CrossRef] [PubMed]

123. Tan, Y.; Song, D.; Wu, L.-H.; Yu, F.; Zhao, M.-H. Serum levels and renal deposition of Clq complement component and its antibodies reflect disease activity of lupus nephritis. *BMRC Nephrol.* 2013, 14, 63. [CrossRef] [PubMed]

124. Enghard, P.; Rieder, C.; Kopetschke, K.; Undeutsch, R.; Biesen, R.; Dragun, D.; Gollasch, M.; Schneider, U.; Aupperle, K.; et al. Urinary CD4 T cells identify SLE patients with proliferative lupus nephritis and can be used to monitor treatment response. *Arthritis Rheum. Dis.* 2013, 73, 277–283. [CrossRef] [PubMed]

125. Menke, J.; Amann, K.; Cavagna, L.; Blettner, M.; Weimann, A.; Schwarting, A.; Kelley, V.R. Colony-Stimulating Factor-1: A Potential Biomarker for Lupus Nephritis. *J. Am. Soc. Nephrol.* 2014, 26, 379–389. [CrossRef] [PubMed]

126. Wu, T.; Xie, J.; Han, J.; Ye, Y.; Singh, S.; Zhou, J.; Li, Y.; Ding, H.; Li, Q.-Z.; Zhou, X.; et al. Insulin-Like Growth Factor Binding Protein-4 as a Marker of Chronic Lupus Nephritis. *PLoS ONE* 2016, 11, e0151491. [CrossRef]

127. Hutcheson, J.; Ye, Y.; Han, J.; Arriens, C.; Saxena, R.; Li, Q.-Z.; Mohan, C.; Wu, T. Resistin as a potential marker of renal disease in lupus nephritis. *Clin. Exp. Immunol.* 2019, 179, 435–443. [CrossRef]

128. Wantanasiri, P.; Satirapoj, B.; Charoenpitakchai, M.; Aramwit, P. Periostin: A novel tissue biomarker correlates with chronicity index and renal function in lupus nephritis. *Lupus* 2015, 24, 835–845. [CrossRef]

129. Fiebeler, A.; Park, J.-K.; Muller, D.N.; Lindschau, C.; Engard, P.; Rieder, C.; Kopetschke, K.; Locke, J.R.; Undeutsch, R.; Biesen, R.; Dragun, D.; Gollasch, M.; Schneider, U.; Aupperle, K.; et al. Urinary CD4 T cells identify SLE patients with proliferative lupus nephritis and can be used to monitor treatment response. *Ann. Rheum. Dis.* 2013, 73, 277–283. [CrossRef] [PubMed]

130. Rothlin, C.V.; Ghosh, S.; Zuniga, E.I.; Oldstone, M.B.; Lemke, G. TAM Receptors Are Pleiotropic Inhibitors of the Innate Immune Response. *Cell 2007*, 131, 1124–1136. [CrossRef]

131. Parodis, I.; Ding, H.; Zickert, A.; Cosson, G.; Fatima, M.; Grönwall, C.; Mohan, C.; Gunnarsson, I. Serum Axl predicts histology-based histopathological outcome following induction therapy. *Lupus Sci. Med.* 2018, 5, e000576. [CrossRef] [PubMed]

132. Möckel, T.; Basta, F.; Weinmann-Menke, J.; Schwarting, A. B cell activating factor (BAFF): Structure, functions, autoimmunity and clinical implications in Systemic Lupus Erythematosus (SLE). *Autoimmun. Rev.* 2020, 20, 102736. [CrossRef]

133. Möckel, T.; Basta, F.; Weinmann-Menke, J.; Schwarting, A. B cell activating factor (BAFF): Structure, functions, autoimmunity and clinical implications in Systemic Lupus Erythematosus (SLE). *Autoimmun. Rev.* 2020, 20, 102736. [CrossRef]

134. A Levy, R.; Gonzalez-Rivera, T.; Khamashta, M.; Fox, N.L.; Jones-Leone, A.; Rubin, B.; Burriss, S.W.; Gairy, K.; van Maurik, A.; A Parodis, I.; Ding, H.; Zickert, A.; Grönwall, C.; Mohan, C.; Gunnarsson, I. Serum Axl predicts histology-based histopathological outcome following induction therapy. *Lupus Sci. Med.* 2018, 5, e000576. [CrossRef] [PubMed]

135.Carlsson, E.; Quist, A.; Davies, J.C.; Midgley, A.; Smith, E.M.; Bruce, I.N.; Beresford, M.W.; Hedrich, C.M. Longitudinal analysis of urinary proteins in lupus nephritis—A pilot study. *Clin. Immunol.* 2022, 236, 108948. [CrossRef] [PubMed]

136. Ichinose, K.; Kitamura, M.; Sato, S.; Fujikawa, K.; Horai, Y.; Matsuoaka, N.; Tsuboi, M.; Nonaka, F.; Shimizu, T.; Fukui, S.; et al. Podocyte foot process width is a prediction marker for complete renal response at 6 and 12 months after induction therapy in lupus nephritis. *Clin. Immunol.* 2018, 197, 161–168. [CrossRef]

137. Ichinose, K.; Kitamura, M.; Sato, S.; Fujikawa, K.; Horai, Y.; Matsuoaka, N.; Tsuboi, M.; Nonaka, F.; Shimizu, T.; Fukui, S.; et al. Podocyte foot process width is a prediction marker for complete renal response at 6 and 12 months after induction therapy in lupus nephritis. *Clin. Immunol.* 2018, 197, 161–168. [CrossRef]

138. Wang, S.; Wu, M.; Chiriboga, L.; Zeck, B.; Belmont, H. Membrane attack complex (mac) deposition in lupus nephritis is associated with hypertension and poor clinical response to treatment. *Semin. Arthritis Rheum.* 2018, 48, 256–262. [CrossRef]

139. Wang, S.; Wu, M.; Chiriboga, L.; Zeck, B.; Goilav, B.; Wang, S.; Jimenez, A.L.; Puttermann, C.; Schwartz, D.; Pullman, J.; et al. Membrane attack complex (MAC) deposition in renal tubules is associated with interstitial fibrosis and tubular atrophy: A pilot study. *Lupus Sci. Med.* 2022, 9, e000576. [CrossRef]

140. Treamtrakanpon, W.; Tantivityakul, P.; Benjachat, T.; Somparrn, P.; Kittikowit, A.; Eiam-Ong, S.; Leelahavanichkul, A.; Hirankarn, N.; Avihingsanon, Y. APRIL, a proliferation-inducing ligand, as a potential marker of lupus nephritis. *Arthritis Res. Ther.* 2012, 14, R252. [CrossRef]
165. Ding, Y.; Yu, X.; Wu, L.; Tan, Y.; Qu, Z.; Yu, F. The Spectrum of C4d Deposition in Renal Biopsies of Lupus Nephritis Patients. *Front. Immunol.* **2021**, *12*, 654652. [CrossRef] [PubMed]

166. Kim, H.; Kim, T.; Kim, M.; Lee, H.Y.; Kim, Y.; Kang, M.S.; Kim, J. Activation of the alternative complement pathway predicts renal outcome in patients with lupus nephritis. *Lupus* **2020**, *29*, 862–871. [CrossRef]

167. Chua, J.S.; Baelde, H.J.; Zandbergen, M.; Wilhelmus, S.; van Es, L.A.; de Fijter, J.W.; Bruijn, J.A.; Bajema, I.M.; Cohen, D. Complement Factor C4d Is a Common Denominator in Thrombotic Microangiopathy. *J. Am. Soc. Nephrol.* **2015**, *26*, 2239–2247. [CrossRef]

168. Cohen, D.; Koopmans, M.; Hovinga, I.C.L.K.; Berger, S.P.; van Groningen, M.R.; Steup-Beekman, G.M.; de Heer, E.; Bruijn, J.A.; Bajema, I.M. Potential for glomerular C4d as an indicator of thrombotic microangiopathy in lupus nephritis. *Arthritis Care Res.* **2008**, *58*, 2460–2469. [CrossRef]

169. Chen, Y.M.; Hung, W.T.; Liao, Y.W.; Hsu, C.Y.; Hsieh, T.Y.; Chen, H.H.; Hsieh, C.W.; Lin, C.T.; Lai, K.L.; Tang, K.T.; et al. Combination immunosuppressant therapy and lupus nephritis outcome: A hospital-based study. *Lupus* **2019**, *28*, 658–666. [CrossRef]

170. Mejia-Vilet, J.M.; Shapiro, J.P.; Zhang, X.L.; Cruz, C.; Zimmerman, G.; Méndez-Pérez, R.A.; Cano-Verduzo, M.L.; Parikh, S.V.; Nagaraja, H.N.; Morales-Buenrostro, L.E.; et al. Association Between Urinary Epidermal Growth Factor and Renal Prognosis in Lupus Nephritis. *Arthritis Rheumatol.* **2020**, *73*, 244–254. [CrossRef]

171. Parodis, I.; Tamirou, F.; Houssiau, F.A. Treat-to-Target in Lupus Nephritis. What is the Role of the Repeat Kidney Biopsy? *Arch. Immunol. et Ther. Exp.* **2022**, *70*, 8. [CrossRef]

172. Parodis, I.; Tamirou, F.; A Houssiau, F. Prediction of prognosis and renal outcome in lupus nephritis. *Lupus Sci. Med.* **2020**, *7*, e000389. [CrossRef] [PubMed]